

References

Structure and Function

1. JW Grisham. Organizational principles of the liver. In Arias I et al (eds): *The Liver: Biology and Pathobiology*. New York, Wiley Blackwell, 2010, pp. 3-16.
2. Dawson PA. Bile formation and enterohepatic circulation. In Johnson LR (ed): *Physiology of the Gastrointestinal Tract*, 4th ed. New York, Academic Press, 2006, pp. 1438-1459.
3. {AU: Provide reference}
4. Mann FC, Brimihall SD, Foster JP. The extrahepatic biliary tract in common domestic and laboratory animals. *Anat Rec*; 1919; 18: 47-66
5. Simon FR. Hormonal regulation of bile secretion. In Arias I et al (eds): *The Liver: Biology and Pathobiology*. New York, Wiley Blackwell, 2010, pp. 323-339.
6. Masyuk AI, Masyk TV, LaRusso NF. Physiology of cholangiocytes. In Johnson LR (ed): *Physiology of the Gastrointestinal Tract*, 4th ed. New York, Academic Press, 2006, pp. 1506-1529.
7. Senoo H, Yoshikawa K, Morii M, et al. Hepatic stellate cell (vitamin A-storing cell) and its relative – past, present, and future. *Cell Biol Int* 34: 1247-1272, 2010.
8. Rojkind M and Rayes-Gordillo K. Hepatic stellate cells. In Arias I et al (eds): *The Liver: Biology and Pathobiology*. New York, Wiley Blackwell, 2010, pp. 407-432.
9. Cheng JH, She H, Han Y-P, et al. Wnt antagonism inhibits hepatic stellate cell activation and hepatic fibrosis. *Am J Physiol (Gastrointest Liver Physiol)* 294: G39-G49, 2007.

10. IJzer J, Roskams T, Molenbeek RF, et al. Morphological characterisation of portal myofibroblasts and hepatic stellate cells in the normal dog liver. *Comparative Hepatology* 5: 7-13, 2006.
11. Wallace K, Burt AD, Wright M. Liver fibrosis. *Biochem J* 411: 1-182008.
12. {AU: Provide reference}
13. DeLeve LD. The hepatic sinusoidal endothelial cell: morphology, function, and pathobiology. In Arias I et al (eds): *The Liver: Biology and Pathobiology*. New York, Wiley Blackwell, 2010, pp. 373-388.
14. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on hepatic endothelial cells. *J Immunology* 169: 983–992, 2002.
15. Navarro-Alvarez N, Soto-Gutierrez A, Kobayashi N. Hepatic stem cells and liver development. *Methods Mol Biol* 640: 181-236, 2010.
16. Schwartz RE, Verfaillie C. Hepatic stem cells. *Methods Mol Biol* 640: 167-179, 2010.
17. Specht A, Fiske L, Erger K, et al. Glycogen storage disease type Ia in canines: a model for human metabolic and genetic liver disease. *J Biomed and Biotech* 2011: 1-9, 2011
18. Bermingham, EN, Thomas DG, Morris PJ, et al. Energy requirements of adult cats. *Brit J Nutr* 103: 1083-1093, 20010.
19. Morris JG, Rogers QR. Ammonia intoxication in the near adult cat as a result of a dietary deficiency of arginine. *Science* 199: 431-432, 1978.
20. MacDonald ML, Rogers QR, Morris JG. Nutrition of the domestic cat, a domestic carnivore. *Ann Rev Nutr* 4: 521-562, 1984.
21. Rogers QA, Morris JG. Lack of hepatic enzyme adaptation to low and high levels of dietary protein in the adult cat. *Enzyme* 22: 348-356, 1977.

22. Xenoulis PG, Steiner JM. Lipid metabolism and hyperlipidemia in the dog. *Vet J* 183: 12-21, 2010.
23. Demacker PN, van Heijst PJ, Hak-Lemmers HL, et al. A study of the lipid transport system in the cat. *Atherosclerosis* 66: 113-123, 1987.
24. Temel RE, Brown JM. A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport. *W J Gastro* 16: 5946-5952, 2010.
25. Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: Fad or future of liver disease? *World J Gastro* 17: 2536-2542, 2011.
26. Favier RP, Spee B, Penning LC, et al. Copper-induced hepatitis: the COMMD1 deficient dog as a translational animal model for human chronic hepatitis. *Vet Q* 31: 49-60, 2011
27. Hoffmann G. Copper-associated liver disease. *Vet Clin Small Anim* 39: 489-511, 2009.
28. Esteller A. Physiology of bile secretion. *World J Gastro* 14: 5641-5619, 2008.
29. Prins M, Schellens CJMM, van Leeuwen MW, et al. Coagulation disorders in dogs with hepatic disease. *Vet J* 185: 163-168, 2010.
30. Mills BM, Zaya MJ, Walters RR, et al. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. *Am Soc Pharm Exp Therap* 38: 396-404, 2010.
31. Shou M, Norcross R, Sandig G, et al. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes P50. *Drug Metab Disp* 31: 1161-1169, 2003.
32. Mealey KL, Jabbes M, Specner E, et al. Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. *Xenobiotica* 38: 1305-1312, 2008.
33. Chauret N, Gauthier A, Martin J, et al. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. *Drug Metab Disp* 25: 1130-1136, 1997.

34. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. *AAPS Journal* 8:E101-E111, 2006.
35. Graham MJ, Bell AR, Crewe HK, et al. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.
36. Zhang et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. *Science* 2002; 298: 422-424.
37. Meyer HP, Rothuizen J. Increased free cortisol in plasma of dogs with portosystemic encephalopathy. *Domestic Animal Endocrin* 11: 317-322m 1994,
38. Rothuizen J, Biewenga WJ, Mol JA. Chronic glucocorticoid excess and impaired osmoregulation of vasopressin release in dogs with hepatic encephalopathy. *Domestic Animal Endocrin* 12: 13-24, 1995.
39. Rothuizen J, de Kok Y, Slob A, et al. GABAergic inhibition of the pituitary release of adrenocorticotropin and melanotropin is impaired in dogs with hepatic encephalopathy. *Domestic Animal Endocrin* 13: 59-68, 1996.
40. Limmer A, Knolle PA. Liver sinusoidal endothelial cells: a new type of organ-resident antigen-presenting cell. *Arch Immunol Therap Experiment* 49: S7-S11, 2001.
41. Knolle PA, Gerken G. Local control of the immune response in the liver. *Immunol Rev* 174: 21-34, 2000.
42. {AU: Provide reference}
43. Fausto N and JS Campbell. Liver regeneration. In Arias I et al (eds): *The Liver: Biology and Pathobiology*. New York, Wiley Blackwell, 2010, pp. 549-567.
44. Mortensen KE, Revhaug A. Liver regeneration in surgical animal models - a historical perspective and clinical implications. *Eur Surg Res* 46: 1-18, 2011.

45. Ren X, Hu B, Colletti LM. IL-22 is involved in liver regeneration after hepatectomy. *Am J Physiol (Gastrointest Liver Physiol)* 298: G74-G80, 2009.

46. Fausto N. Liver regeneration. *J. Hepatology* 2000; 32: 19-31.

47. Ogata A. Short term effect of portal arterialization on hepatic protein synthesis and endotoxemia after extended hepatectomy in dogs. *J. Gastroenterol. Hepatol.* 1997; 12: 633-639.

48. Michalopoulos GK. Liver regeneration. *J Cell Physio* 213: 286-300, 2007.

HISTORY, PHYSICAL EXAMINATION

1. Zakim D. Pathophysiology of liver disease. In: Smith LH, Thier SO, eds. *Pathophysiology: The Biological Principles of Disease*, 2nd ed. Philadelphia, PA: WB Saunders Co, 1985; 1253-1298.

2. Silverman J, Kurtz SM, Draper J. *Skills for Communicating with Patients*, 2nd ed. Abingdon, UK: Radcliffe Publishing, 2004.

3. Kurtz SM, Silverman J, Draper J. *Teaching and Learning Communication Skills in Medicine*. 2nd ed. Abingdon, UK: Radcliffe Publishing, 2005.

4. Fausto N, Webber EM. Liver regeneration. In: Arias M, Boyer JL, Fausto N, et al, eds. *The Liver: Biology and Pathobiology*, 3rd ed. New York, NY: Raven Press, 1994; 1059-1084.

5. Rothuizen J, Meyer HP. History, physical examination, and signs of liver disease. In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat*. Philadelphia, PA: WB Saunders Co, 2000; 1272-1277.

6. van den Ingh TSGAM, Rothuizen J, van den Brom WE. Extrahepatic cholestasis in the dog and the differentiation of extrahepatic and intrahepatic cholestasis. *Vet Q* 1986; 150: 1986.

7. Center SA, Magne ML. Historical, physical examination and clinicopathological features of portosystemic vascular anomalies in the dog and cat. *Semin Vet Med Surg (Small Anim)* 1991; 5: 75.
8. WSAVA. Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Saunders Elsevier, 2006; 2.
9. Webster CRL. History, clinical signs and physical findings in hepatobiliary disease. In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat*. St. Louis, MO: Elsevier Saunders, 2005; 1422-1434.
10. Jacobson LS, Kirberger RM, Nesbitt JW. Hepatic ultrasonography and pathological findings in dogs with hepatocutaneous syndrome: New concepts. *J Vet Intern Med* 1995; 9: 399.
11. Conn HO, Bircher J. *Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates*. East Lansing, MI: Medi-Ed Press, 1988.
12. Dial SM. Clinicopathologic evaluation of the liver. *Vet Clin North Am Small Anim Pract* 1995; 25: 257.
13. WSAVA. Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Saunders Elsevier, 2006; 5.
14. van den Ingh TSGAM, Rothuizen J, van Zinnicq Bergman HMS. Destructive cholangiolitis in seven dogs. *Vet Q* 1988; 10: 240.
15. Andersson M, Sevelius E. Breed, sex and age distribution in dogs with chronic liver disease—a demographic study. *J Small Anim Pract* 1991; 32: 1.
16. van den Ingh TSGAM, Rothuizen J. Lobular dissecting hepatitis in juvenile and young adult dogs. *J Vet Intern Med* 1994; 8: 217.

17. Spee B, Mandigers PJ, Arends B, et al. Differential expression of copper-associated and oxidative stress related proteins in a new variant of copper toxicosis in Doberman pinschers. *Comp Hepatol* 2005; 4(1): 3.
18. Crawford MA, Schall WD, Jensen RK, et al. Chronic active hepatitis in 26 Doberman pinschers. *JAVMA* 1985; 187: 1343-1350.
19. Mandigers PJ, van den Ingh TS, Bode P, et al. Improvement in liver pathology after 4 months of D-penicillamine in 5 Doberman pinschers with subclinical hepatitis. *J Vet Intern Med* 2005; 19: 40-43.
20. Speeti M, Ihantola M, Westermarck E. Subclinical versus clinical hepatitis in the Doberman: Evaluation of changes in blood parameters. *J Small Anim Pract* 1996; 37: 465.
21. Rolfe DS, Twedt DC. Copper-associated hepatopathies in dogs. *Vet Clin North Am Small Anim Pract* 1995; 25: 399.
22. Haywood S, Rutgers, HC, Christian MK. Hepatitis and copper accumulation in Skye terriers. *Vet Pathol* 1988; 25: 408-414.
23. Klomp AE, van De SB, Klomp LW, et al. The ubiquitous expressed MURR1 protein is absent in canine copper toxicosis. *J Hepatol* 2003; 39: 703-709.
24. Mandigers PJ, van den Ingh TSGAM, Spee B, et al. Chronic hepatitis in Doberman pinschers. A review. *Vet Q* 2004; 26: 98-106.
25. Spee B, Arends B, van den Ingh TSGAM, et al. Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver disease in dogs. *J Vet Intern Med* 2006; 20: 1085-1092.
26. Hoffmann G, van den Ingh TSGAM, Bode P, et al. Copper-associated chronic hepatitis in Labrador retrievers. *J Vet Intern Med* 2006; 20: 856-861

27. Wijmenga C, Klomp LW. Molecular regulation of copper excretion in the liver. *Proc Nutr Soc* 2004; 63: 31-39.
28. Meyer HP, Rothuizen J, Ubbink JB, et al. Increasing incidence of hereditary intrahepatic portosystemic shunts in Irish wolfhounds in the Netherlands 1984-1992. *Vet Rec* 1995; 136(1): 13-16.
29. van Straten G, Leegwater PAJ, de Vries M, et al. Inherited congenital extrahepatic portosystemic shunts in Cairn terriers. *J Vet Intern Med* 2005; 19(3): 321-324.
30. Batt RM, Twedt DC. Canine gastrointestinal disease. In: Wills JM, Simpson KW, eds. *Waltham Book of Clinical Nutrition of the Dog & Cat*, 1st ed. Pergamon Press, 1994.
31. Dillon R. The liver in systemic disease: An innocent bystander. *Vet Clin North Am Small Anim Pract* 1985; 15: 97.
32. Butterworth RF. Hepatic encephalopathy. In: Arias IM, ed. *Liver: Biology and Pathobiology*, 3rd ed. New York, NY: Raven Press, 1994; 1193-1208.
33. Center SA, Crawford MA, Guida L, et al. A retrospective study of 77 cats with severe hepatic lipidosis, 1975-1990. *J Vet Intern Med* 1993; 7: 349.
34. Butterworth RF. Neuroactive amino acids in hepatic encephalopathy. *Metab Brain Dis* 1996; 11: 165-173.
35. Meyer HP. Chronic hepatic encephalopathy: Studies into the pathogenesis and treatment in the dog. PhD Thesis. State University of Utrecht, The Netherlands, 1998.
36. Jones EA, Schafer DF, Ferenci P, et al. The GABA hypothesis of the pathogenesis of hepatic encephalopathy: Current status. *Yale J Biol Med* 1984; 57: 301.

37. Rothuizen J, Mol JA. The pituitary-adrenocortical system in canine hepatoencephalopathy. In: van Wimersma Greidanus TB, ed. *Frontiers of Hormone Research*. Basel, Karger, 1987; 28-36.
38. Rothuizen J, Biewenga WJ, Mol JA. Chronic glucocorticoid excess and impaired osmoregulation of vasopressin release in dogs with hepatic encephalopathy. *Domest Anim Endocrinol* 1995; 12: 13.
39. Biewenga WJ, Rijnberk A, Mol JA. Osmoregulation of systemic vasopressin release during long-term glucocorticoid excess: A study in dogs with hyperadrenocorticism. *Acta Endocrinol (Copenh)*. 1991; 124: 583-588.
40. Schipper L, Spee B, Rothuizen J, et al. Characterisation of 11 beta-hydroxysteroid dehydrogenases in feline kidney and liver. *Biochim Biophys Acta* 2004 Jan 20; 1688(1): 68-77.
41. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. *Am J Physiol* 1992; 263: E1125-30.
42. Westropp JL, Buffington CA, Chew D. Feline lower urinary tract diseases. In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat*. St. Louis, MO: Elsevier Saunders, 2005; 1849.
43. Sorenson JL, Ling GV. Metabolic and genetic aspects of urate urolithiasis in Dalmatians. *JAVMA* 1993; 203: 857.
44. Leifer CE, Peterson ME, Matus RE, et al. Hypoglycemia associated with nonislet cell tumor in 13 dogs. *JAVMA* 1985; 186: 53.
45. Rothuizen J, van den Brom WE, Fevery J. The origins and kinetics of bilirubin in dogs with hepatobiliary and haemolytic diseases. *J Hepatol* 1992; 15: 17.

46. Rothuizen J, van den Brom WE. Bilirubin metabolism in canine hepatobiliary and haemolytic disease. *Vet Q* 1987; 9: 235.
47. Badylak S, Dodds WJ, Van Vleet JF. Plasma coagulation factor abnormalities in dogs with naturally occurring hepatic disease. *Am J Vet Res* 1983; 44: 2336-2340.
48. Badylak S, Van Vleet JF. Alterations of prothrombin time and activated partial thromboplastin time in dogs with hepatic disease. *Am J Vet Res* 1981; 42: 2053-2056.
49. Bigge LA, Brown DJ, Pennick DG. Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996). *J Am Anim Hosp Assn* 2001; 37: 228-233.
50. Mount ME, Kim BU, Kass PH. Use of a test for proteins induced by vitamin K absence or antagonism in diagnosis or anticoagulant poisoning in dogs. *JAVMA* 2003; 222: 194-198.
51. Center SA. Current considerations for evaluating liver function. In: August JR, ed. *Consultations in Feline Internal Medicine*, vol. 5. St. Louis, MO: Elsevier Saunders, 2006; 89-108.
52. van den Ingh TSGAM, Rothuizen J, Meyer HP. Circulatory disorders of the liver in dogs and cats. *Vet Q* 1995; 17: 70.
53. Gerritzen-Bruing MJ, van den Ingh TSGAM, Rothuizen J. Diagnostic value of fasting plasma ammonia and bile acid concentrations in identification of portosystemic shunting in dogs. *J Vet Intern Med* 2006; 20: 13-19.
54. Sterczer A, Meyer HP, Boswijk HC, et al. Evaluation of ammonia measurements in dogs with two analysers for use in veterinary practice. *Vet Rec* 1999; 144(19): 523-526.
55. Szatmari V, Rothuizen J, van den Ingh TSGAM, et al. Ultrasonographic findings in dogs with hyperammonemia: 90 cases. *JAVMA* 2004; 224: 717-727.

Diagnostic Evaluation

1. Zinkl JG, Bush RM, Cornelius CE et al. Comparative studies on plasma and tissue sorbitol, glutamic, lactic and hydroxybutyric dehydrogenase and transaminase activities in the dog. *Res Vet Sci* 1971;12:211-214.
2. Dossin O, Rives A, Germain C et al. Pharmacokinetics of liver transaminases in healthy dogs: potential clinical relevance for assessment of liver damage. *J Vet Intern Med* 2005;19:442.
(Abstract)
3. Nilkumhang P, Thornton JR. Plasma and tissue enzyme activities in the cat. *J Small Anim Pract* 1979;20:169-174.
4. Horiuchi S, Kamimoto Y, Morino Y. Hepatic clearance of rat liver aspartate aminotransferase isozymes: evidence for endocytotic uptake via different binding sites on sinusoidal liver cells. *Hepatology* 1985;5:376-382.
5. Gaskill CL, Burton SA, Gelens HC et al. Effects of phenobarbital treatment on serum thyroxine and thyroid-stimulating hormone concentrations in epileptic dogs. *J Am Vet Med Assoc* 1999;215:489-496.
6. Nagode LA, Frajola WJ, Loeb WF. Enzyme activities of canine tissue. *Am J Vet Res* 1966;27:1385-1393.
7. Nilkumhang P, Thornton JR. Plasma and tissue enzyme activities in the cat. *J Small Anim Pract* 1979;20:169-174.
8. Keller P. Enzyme activities in the dog: tissue analyses, plasma values, and intracellular distribution. *Am J of Vet Res* 1981;42:575-582.

9. Center SA, Baldwin BH, King JM et al. Hematologic and biochemical abnormalities associated with induced extrahepatic bile duct obstruction in the cat. *Am J Vet Res* 1983;44:1822-1829.
10. Everett RM, Duncan JR, Prasse KW. Alkaline phosphatase, leucine aminopeptidase, and alanine aminotransferase activities with obstructive and toxic hepatic disease in cats. *Am J Vet Res* 1977;38:963-966.
11. Hoffman WE, Renegar WE, Dorner JL. Alkaline phosphatase and alkaline phosphatase isoenzymes in the cat. *Vet Clin Pathol* 1977;6:21-24.
12. Foster DJ, Thoday KL. Tissue sources of serum alkaline phosphatase in 34 hyperthyroid cats: a qualitative and quantitative study. *Res Vet Sci* 2000;68:89-94.
13. Wiedmeyer CE, Solter PE, Hoffmann WE. Kinetics of mRNA expression of alkaline phosphatase isoenzymes in hepatic tissues from glucocorticoid-treated dogs. *Am J Vet Res* 2002;63:1089-1095.
14. Bengmark S, Olsson R. Elimination of alkaline phosphatases from serum in dog after intravenous injection of canine phosphatases from bone and intestine. *Acta Chir Scand* 1974;140:1-6.
15. Hoffmann WE, Dorner JL. Disappearance rates of intravenously injected canine alkaline phosphatase isoenzymes. *Am J Vet Res* 1977;38:1553-1556.
16. Hoffmann WE, Renegar WE, Dorner JL. Serum half-life of intravenously injected intestinal and hepatic alkaline phosphatase isoenzymes in the cat. *Am J Vet Res* 1977;38:1637-1639.
17. Solter PF, Hoffmann WE. Solubilization of liver alkaline phosphatase isoenzyme during cholestasis in dogs. *Am J Vet Res* 1999;60:1010-1015.

18. Center SA, Slater MR, Manwarren T et al. Diagnostic efficacy of serum alkaline phosphatase and gamma-glutamyltransferase in dogs with histologically confirmed hepatobiliary disease: 270 cases (1980-1990). *J Am Vet Med Assoc* 1992;201:1258-1264.
19. Center SA, Baldwin BH, Dillingham S et al. Diagnostic value of serum gamma-glutamyl transferase and alkaline phosphatase activities in hepatobiliary disease in the cat. *J Am Vet Med Assoc* 1986;188:507-510.
20. Lawler DF, Keltner DG, Hoffman WE et al. Benign familial hyperphosphatasemia in Siberian huskies. *Am J Vet Res* 1996;57:612-617.
21. Gallagher AE, Panciera DL, Panciera RJ. Hyperphosphatasemia in Scottish terriers: 7 cases. *J Vet Intern Med* 2006;20:418-421.
22. Center SA, Randolph JF, Manwarren T et al. Effect of colostrum ingestion on gamma-glutamyltransferase and alkaline phosphatase activities in neonatal pups. *Am J Vet Res* 1991;52:499-504.
23. Guyton AC, Hall JE. The Liver as an Organ. In: Guyton AC, Hall JE, eds. *Textbook of Medical Physiology*. 11th ed. Philadelphia: Saunders, 2006;859-864.
24. Thomas LA, Brown SA. Relationship between colloid osmotic pressure and plasma protein concentration in cattle, horses, dogs, and cats. *Am J Vet Res* 1992;53:2241-2244.
25. Morris MA, Preddy L. Glycosylation accelerates albumin degradation in normal and diabetic dogs. *Biochem Med Metab Biol* 1986;35:267-270.
26. Lowrie M, Penderis J, McLaughlin M et al. Steroid responsive meningitis-arteritis: a prospective study of potential disease markers, prednisolone treatment, and long-term outcome in 20 dogs (2006-2008). *J Vet Intern Med* 2009;23:862-870.

27. Lowrie M, Penderis J, Eckersall PD et al. The role of acute phase proteins in diagnosis and management of steroid-responsive meningitis arteritis in dogs. *Vet J* 2009;182:125-130.
28. Tecles F, Caldin M, Zanella A et al. Serum acute phase protein concentrations in female dogs with mammary tumors. *J Vet Diagn Invest* 2009;21:214-219.
29. Bayramli G, Ulutas B. Acute phase protein response in dogs with experimentally induced gastric mucosal injury. *Vet Clin Pathol* 2008;37:312-316.
30. Badylak SF, Dodds WJ, Van Vleet JF. Plasma coagulation factor abnormalities in dogs with naturally occurring hepatic disease. *Am J Vet Res* 1983;44:2336-2340.
31. Lisciandro SC, Hohenhaus A, Brooks M. Coagulation abnormalities in 22 cats with naturally occurring liver disease. *J Vet Intern Med* 1998;12:71-75.
32. Prins M, Schellens CJ, van Leeuwen MW et al. Coagulation disorders in dogs with hepatic disease. *Vet J* 2010;185:163-168.
33. Mount ME, Kim BU, Kass PH. Use of a test for proteins induced by vitamin K absence or antagonism in diagnosis of anticoagulant poisoning in dogs: 325 cases (1987-1997). *J Am Vet Med Assoc* 2003;222:194-198.
34. Center SA, Warner K, Corbett J et al. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. *J Vet Intern Med* 2000;14:292-297.
35. Toulza O, Center SA, Brooks MB et al. Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. *J Am Vet Med Assoc* 2006;229:1761-1771.
36. Watson PJ, Herrtage ME. Medical management of congenital portosystemic shunts in 27 dogs-a retrospective study. *J Small Anim Pract* 1998;39:62-68.

37. Meijer AJ, Lamers WH, Chamuleau RA. Nitrogen metabolism and ornithine cycle function. *Physiol Rev* 1990;70:701-748.
38. Walker MC, Hill RC, Guilford WG et al. Postprandial venous ammonia concentrations in the diagnosis of hepatobiliary disease in dogs. *J Vet Intern Med* 2001;15:463-466.
39. Johnson CA, Armstrong PJ, Hauptman JG. Congenital portosystemic shunts in dogs: 46 cases (1979-1986). *J Am Vet Med Assoc* 1987;191:1478-1483.
40. Tisdall PL, Hunt GB, Bellenger CR et al. Congenital portosystemic shunts in Maltese and Australian cattle dogs. *Aust Vet J* 1994;71:174-178.
41. Ruland K, Fischer A, Hartmann K. Sensitivity and specificity of fasting ammonia and serum bile acids in the diagnosis of portosystemic shunts in dogs and cats. *Vet Clin Pathol* 2010;39:57-64.
42. Walker MC, Hill RC, Guilford WG et al. Postprandial venous ammonia concentrations in the diagnosis of hepatobiliary disease in dogs. *J Vet Intern Med* 2001;15:463-466.
43. Strombeck DR, Meyer DJ, Freedland RA. Hyperammonemia due to a urea cycle enzyme deficiency in two dogs. *J Am Vet Med Assoc* 1975;166:1109-1111.
44. Battersby IA, Giger U, Hall EJ. Hyperammonaemic encephalopathy secondary to selective cobalamin deficiency in a juvenile Border collie. *J Small Anim Pract* 2005;46:339-344.
45. Morris JG, Rogers QR. Ammonia intoxication in the near-adult cat as a result of a dietary deficiency of arginine. *Science* 1978;199:431-432.
46. Sterczer A, Meyer HP, Boswijk HC et al. Evaluation of ammonia measurements in dogs with two analysers for use in veterinary practice. *Vet Rec* 1999;144:523-526.
47. Goggs R, Serrano S, Szladovits B et al. Clinical investigation of a point-of-care blood ammonia analyzer. *Vet Clin Pathol* 2008;37:198-206.

48. Rothuizen J, van den Ingh TS. Rectal ammonia tolerance test in the evaluation of portal circulation in dogs with liver disease. *Res Vet Sci* 1982;33:22-25.
49. Simpson KW, Meyer DJ, Boswood A et al. Iron status and erythrocyte volume in dogs with congenital portosystemic vascular anomalies. *J Vet Intern Med* 1997;11:14-19.
50. Danielsson B, Ekman R, Johansson BG et al. Plasma lipoprotein changes in experimental cholestasis in the dog. *Clin Chim Acta* 1977;80:157-170.
51. Aguirre A, Center S, Randolph J et al. Gallbladder disease in Shetland Sheepdogs: 38 cases (1995-2005). *J Am Vet Med Assoc* 2007;231:79-88.
52. Xenoulis PG, Suchodolski JS, Levinski MD et al. Serum liver enzyme activities in healthy Miniature Schnauzers with and without hypertriglyceridemia. *J Am Vet Med Assoc* 2008;232:63-67.
53. Bostwick DR, Twedt DC. Intrahepatic and extrahepatic portal venous anomalies in dogs: 52 cases (1982-1992). *J Am Vet Med Assoc* 1995;206:1181-1185.
54. Leifer CE, Peterson ME, Matus RE et al. Hypoglycemia associated with nonislet cell tumor in 13 dogs. *J Am Vet Med Assoc* 1985;186:53-55.
55. Rothuizen J, van den Brom WE, Fevery J. The origins and kinetics of bilirubin in dogs with hepatobiliary and haemolytic diseases. *J Hepatol* 1992;15:17-24.
56. Morley P, Mathes M, Guth A et al. Anti-erythrocyte antibodies and disease associations in anemic and nonanemic dogs. *J Vet Intern Med* 2008;22:886-892.
57. Rothuizen J, van d, I. Covalently protein-bound bilirubin conjugates in cholestatic disease of dogs. *Am J Vet Res* 1988;49:702-704.
58. Center SA. Serum Bile-Acids in Companion Animal Medicine. *Vet Clin North Am-Small Anim Pract* 1993;23:625-657.

59. Center SA, Leveille CR, Baldwin BH et al. Direct spectrometric determination of serum bile acids in the dog and cat. *Am J Vet Res* 1984;45:2043-2050.
60. Bunch SE, Center SA, Baldwin BH et al. Radioimmunoassay of conjugated bile acids in canine and feline sera. *Am J Vet Res* 1984;45:2051-2054.
61. Fujii T, Yanagisawa J, Nakayama F. Absorption of bile acids in dog as determined by portal blood sampling: evidence for colonic absorption of bile acid conjugates. *Digestion* 1988;41:207-214.
62. Rabin B, Nicolosi RJ, Hayes KC. Dietary influence on bile acid conjugation in the cat. *J Nutr* 1976;106:1241-1246.
63. Nally CV, McMullin LJ, Clanachan AS et al. Periodic gallbladder contraction maintains bile acid circulation during the fasting period: a canine study. *Br J Surg* 1987;74:1134-1138.
64. Wilson FA. Intestinal transport of bile acids. *Am J Physiol* 1981;241:G83-G92.
65. Ruaux CG, Steiner JM, Williams DA. Postprandial changes in serum unconjugated bile acid concentrations in healthy beagles. *Am J Vet Res* 2002;63:789-793.
66. Center SA, Manwarren T, Slater MR et al. Evaluation of twelve-hour preprandial and two-hour postprandial serum bile acids concentrations for diagnosis of hepatobiliary disease in dogs. *J Am Vet Med Assoc* 1991;199:217-226.
67. Center SA, Baldwin BH, Erb HN et al. Bile acid concentrations in the diagnosis of hepatobiliary disease in the dog. *J Am Vet Med Assoc* 1985;187:935-940.
68. Center SA, Erb HN, Joseph SA. Measurement of Serum Bile-Acids Concentrations for Diagnosis of Hepatobiliary Disease in Cats. *J Am Vet Med Assoc* 1995;207:1048-1054.

69. Tisdall PLC, Hunt GB, Tsoukalas G et al. Post-prandial serum bile acid concentrations and ammonia tolerance in Maltese dogs with and without hepatic vascular anomalies. *Aust Vet J* 1995;72:121-126.
70. Gerritzen-Bruning MJ, van den Ingh TS, Rothuizen J. Diagnostic value of fasting plasma ammonia and bile acid concentrations in the identification of portosystemic shunting in dogs. *J Vet Intern Med* 2006;20:13-19.
71. Melgarejo T, Williams DA, O'Connell NC et al. Serum unconjugated bile acids as a test for intestinal bacterial overgrowth in dogs. *Dig Dis Sci* 2000;45:407-414.
72. Bauer NB, Schneider MA, Neiger R et al. Liver disease in dogs with tracheal collapse. *J Vet Intern Med* 2006;20:845-849.
73. Bridger N, Glanemann B, Neiger R. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. *J Vet Intern Med* 2008;22:873-878.
74. Balkman CE, Center SA, Randolph JF et al. Evaluation of urine sulfated and nonsulfated bile acids as a diagnostic test for liver disease in dogs. *J Am Vet Med Assoc* 2003;222:1368-1375.
75. Trainor D, Center SA, Randolph F et al. Urine sulfated and nonsulfated bile acids as a diagnostic test for liver disease in cats. *J Vet Intern Med* 2003;17:145-153.
76. Steiner JM, Williams DA, Bunch SE. Bile acids diagnostic test believed to contain limitations. *J Am Vet Med Assoc* 2003;223:429-430.
77. Steiner JM, Williams DA, Twedt DC. Urine sulfated and nonsulfated bile acids as a diagnostic test for liver disease in cats. *J Vet Intern Med* 2003;17:605-606.
78. Moeller EM, Steiner JM, Williams DA et al. Kinetic analysis of demethylation of 13C-aminopyrine in healthy dogs. *Am J of Vet Res* 2004;65:159-162.

79. Chiaramonte D, Steiner JM, Broussard JD et al. Use of a ¹³C-aminopyrine blood test: first clinical impressions. *Can J Vet Res* 2003;67:183-188.
80. Silva S, Wyse CA, Goodfellow MR et al. Assessment of liver function in dogs using the (13)C-galactose breath test. *Vet J* 2010;185:152-156.
81. Neumann S, Welling H, Thuere S. Evaluation of serum L-phenylalanine concentration as indicator of liver disease in dogs: a pilot study. *J Am Anim Hosp Assoc* 2007;43:193-200.
82. Archer J. Urine analysis. In: Villiers E, Blackwood L, eds. *BSAVA Manual of Canine and Feline Clinical Pathology*. 2nd ed. Quedgeley: BSAVA, 2005;149-168.
83. Center SA, Magne ML. Historical, physical examination, and clinicopathologic features of portosystemic vascular anomalies in the dog and cat. *Semin Vet Med Surg (Small Anim)* 1990;5:83-93.
84. Stanton ME, Bright RM. Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review. *J Vet Intern Med* 1989;3:238-244.
85. Bunch SE, Jordan HL, Sellon RK et al. Characterization of iron status in young dogs with portosystemic shunt. *Am J Vet Res* 1995;56:853-858.
86. Poldervaart JH, Favier RP, Penning LC et al. Primary hepatitis in dogs: a retrospective review (2002-2006). *J Vet Intern Med* 2009;23:72-80.
87. Goldstein RE, Lin RC, Langston CE et al. Influence of infecting serogroup on clinical features of leptospirosis in dogs. *J Vet Intern Med* 2006;20:489-494.
88. Holmes NG, Herrtage ME, Ryder EJ et al. DNA marker C04107 for copper toxicosis in a population of Bedlington terriers in the United Kingdom. *Vet Rec* 1998;142:351-352.
89. Lee SA, Fillipich LJ, Hyun C. Prevalence of the exon 2 deletion of the COMMD1 gene in Australian Bedlington terriers. *J Genet* 2007;86:289-291.

90. Kanemoto H, Ohno K, Sakai M et al. Blood hyaluronic acid as a marker for canine cirrhosis. *J Vet Med Sci* 2009;71:1251-1254.
91. Larson MM. The Liver and Spleen. In: Thrall DE, ed. *Textbook of Veterinary Diagnostic Radiology*. 5th ed. St Louis: Saunders, 2007;667-692.
92. Schwarz LA, Penninck DG, Leveille-Webster C. Hepatic abscesses in 13 dogs: a review of the ultrasonographic findings, clinical data and therapeutic options. *Vet Radiol Ultrasound* 1998;39:357-365.
93. Armstrong JA, Taylor SM, Tryon KA et al. Emphysematous cholecystitis in a Siberian husky. *Can Vet J* 2000;41:60-62.
94. Kirpensteijn J, Fingland RB, Ulrich T et al. Cholelithiasis in dogs: 29 cases (1980-1990). *J Am Vet Med Assoc* 1993;202:1137-1142.
95. Bromel C, Smeak DD, Leveille R. Porcelain gallbladder associated with primary biliary adenocarcinoma in a dog. *J Am Vet Med Assoc* 1998;213:1137-9, 1131.
96. Sergeeff JS, Armstrong PJ, Bunch SE. Hepatic abscesses in cats: 14 cases (1985-2002). *J Vet Int Med* 2004;18:295-300.
97. Herrgesell EJ, Hornof WJ, Koblik PD. Percutaneous ultrasound-guided trans-splenic catheterization of the portal vein in the dog. *Vet Radiol Ultrasound* 1999;40:509-512.
98. Miller MW, Fossum TW, Bahr AM. Transvenous retrograde portography for identification and characterization of portosystemic shunts in dogs. *J Am Vet Med Assoc* 2002;221:1586-90.
99. Weisse C, Mondschein JI, Itkin M et al. Use of a percutaneous atrial septal occluder device for complete acute occlusion of an intrahepatic portosystemic shunt in a dog. *J Am Vet Med Assoc* 2005;227:249-52.

100. Gaschen L. Update on hepatobiliary imaging. *Vet Clin North Am Small Anim Pract* 2009;39:439-467.
101. Yeager AE, Mohammed H. Accuracy of ultrasonography in the detection of severe hepatic lipidosis in cats. *Am J Vet Res* 1992;53:597-599.
102. Feeney DA, Anderson KL, Ziegler LE et al. Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. *Am J Vet Res* 2008;69:212-221.
103. Cuccovillo A, Lamb CR. Cellular features of sonographic target lesions of the liver and spleen in 21 dogs and a cat. *Vet Radiol Ultrasound* 2002;43:275-278.
104. O'Brien RT, Iani M, Matheson J et al. Contrast harmonic ultrasound of spontaneous liver nodules in 32 dogs. *Vet Radiol Ultrasound* 2004;45:547-553.
105. Newell SM, Selcer BA, Girard E et al. Correlations between ultrasonographic findings and specific hepatic diseases in cats: 72 cases (1985-1997). *J Am Vet Med Assoc* 1998;213:94-98.
106. Ramstedt KL, Center SA, Randolph JF et al. Changes in gallbladder volume in healthy dogs after food was withheld for 12 hours followed by ingestion of a meal or a meal containing erythromycin. *Am J Vet Res* 2008;69:647-651.
107. Bromel C, Barthez PY, Leveille R et al. Prevalence of gallbladder sludge in dogs as assessed by ultrasonography. *Vet Radiol Ultrasound* 1998;39:206-210.
108. Gaillot HA, Penninck DG, Webster CR et al. Ultrasonographic features of extrahepatic biliary obstruction in 30 cats. *Vet Radiol Ultrasound* 2007;48:439-447.
109. Pike FS, Berg J, King NW et al. Gallbladder mucocele in dogs: 30 cases (2000-2002). *J Am Vet Med Assoc* 2004;224:1615-1622.

110. d'Anjou MA, Penninck D, Cornejo L et al. Ultrasonographic diagnosis of portosystemic shunting in dogs and cats. *Vet Radiol Ultrasound* 2004;45:424-437.
111. Lamb CR. Ultrasonography of portosystemic shunts in dogs and cats. *Vet Clin North Am Small Anim Pract* 1998;28:725-753.
112. Szarmari V, Rothuizen J. Ultrasonographic identification and characterization of congenital portosystemic shunts. In: WSAVA Liver Standardization Group, eds. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease*. 1st ed. Philadelphia: Elsevier, 2006;15-40.
113. Sura PA, Tobias KM, Morandi F et al. Comparison of $^{99m}\text{TcO}_4(-)$ trans-splenic portal scintigraphy with per-rectal portal scintigraphy for diagnosis of portosystemic shunts in dogs. *Vet Surg* 2007;36:654-660.
114. Boothe HW, Boothe DM, Komkov A et al. Use of hepatobiliary scintigraphy in the diagnosis of extrahepatic biliary obstruction in dogs and cats: 25 cases (1982-1989). *J Am Vet Med Assoc* 1992;201:134-141.
115. Irausquin RA, Scavelli TD, Corti L et al. Comparative evaluation of the liver in dogs with a splenic mass by using ultrasonography and contrast-enhanced computed tomography. *Can Vet J* 2008;49:46-52.
116. Clifford CA, Pretorius ES, Weisse C et al. Magnetic resonance imaging of focal splenic and hepatic lesions in the dog. *J Vet Intern Med* 2004;18:330-338.
117. Zwingerberger AL, Schwarz T, Saunders HM. Helical computed tomographic angiography of canine portosystemic shunts. *Vet Radiol Ultrasound* 2005;46:27-32.

118. Echandi RL, Morandi F, Daniel WT et al. Comparison of transplenic multidetector CT portography to multidetector CT-angiography in normal dogs. *Vet Radiol Ultrasound* 2007;48:38-44.
119. Seguin B, Tobias KM, Gavin PR et al. Use of magnetic resonance angiography for diagnosis of portosystemic shunts in dogs. *Vet Radiol Ultrasound* 1999;40:251-258.
120. Ludwig LL, McLoughlin MA, Graves TK et al. Surgical treatment of bile peritonitis in 24 dogs and 2 cats: a retrospective study (1987-1994). *Vet Surg* 1997;26:90-98.
121. Willard MD, Weeks BR, Johnson M. Fine-needle aspirate cytology suggesting hepatic lipidosis in four cats with infiltrative hepatic disease. *J Feline Med Surg* 1999;1:215-220.
122. Sepesy LM, Center SA, Randolph JF et al. Vacuolar hepatopathy in dogs: 336 cases (1993-2005). *J Am Vet Med Assoc* 2006;229:246-252.
123. Wang KY, Panciera DL, Al Rukibat RK et al. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). *J Am Vet Med Assoc* 2004;224:75-78.
124. van den Ingh TSGAM, Cullen JM, Twedt DC et al. Morphological classification of biliary disorders of the canine and feline liver. In: WSAVA Liver Standardization Group eds. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases*. 1st ed. Philadelphia: Elsevier, 2006;61-75.
125. Cole TL, Center SA, Flood SN et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. *J Am Vet Med Assoc* 2002;220:1483-1490.
126. Rothuizen J, Desmet VJ, van der Ingh TSGAM et al. Sampling and handling of liver tissue. In: WSAVA Liver Standardization Group eds. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease*. 1st ed. Philadelphia: Elsevier, 2006;5-14.

127. Johnston AN, Center SA, McDonough SP et al. Influence of biopsy specimen size, tissue fixation, and assay variation on copper, iron, and zinc concentrations in canine livers. *Am J Vet Res* 2009;70:1502-1511.

BIOPSY TECHNIQUES

1. Feeney DA, Anderson KL, Ziegler LE, et al. Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. *Am J Vet Res* 69: 212, 2008.

2. Guillot M, Danjou MA, Alexander K, et al. Can sonographic findings predict the results of liver aspirates in dogs with suspected liver disease? *Vet Radiol Ultrasound* 50: 513, 2009.

3. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. *Dig Disc Sci* 26: 388, 1981.

4. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. *Am J Clin Pathol* 94: 747, 1990.

5. Bigge LA, Brown DJ, Penninck DG. Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996). *J Am Anim Hosp Assoc* 37: 228, 2001.

6. Center SA, Warner K, Corbett J, et al. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. *J Vet Intern Med* 14: 292, 2000.

7. Center S A, Warner KL, Corbett JR. PIVKA clotting times in dogs with suspected coagulopathies. *J Vet Intern Med* 12: 214, 1998.

8. Vasanjee SC, Bubenik LJ, Hosgood G, et al. Evaluation of hemorrhage, sample size, and collateral damage for five hepatic biopsy methods in dogs. *Vet Surg* 35: 86, 2006.

9. Fondacaro JV, Guilpin VO, Powers BE, et al. Diagnostic correlation of liver aspiration cytology with histopathology in dogs and cats with liver disease. Proc 17th ACVIM Forum, p. 719, 1999.
10. Wang, KY, Panciera DL, Al-Rukibat RK, et al. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). J Am Vet Med Assoc 224: 75, 2004.
11. Roth L: Comparison of liver cytology and biopsy diagnoses in dogs and cats: 56 cases. Vet Clin Pathol 30: 35, 2001.
12. Weiss DJ, Blauvelt M, Aird B. Cytologic Evaluation of Inflammation in Canine Liver Aspirates. Vet Clin Pathol 30: 193, 2001.
13. Johnston AN, Center SA, McDonough SP, et al. Influence of biopsy specimen size, tissue fixation, and assay variation on copper, iron, and zinc concentrations in canine livers. Am J Vet Res 70: 1502, 2009.
14. Hitt ME, Hanna P, Singh A. Percutaneous transabdominal hepatic needle biopsies in dogs. Am J Vet Res 53: 785, 1992.
15. Barr F. Percutaneous biopsy of abdominal organs under ultrasound guidance. J Small Anim Pract 36: 105, 1995.
16. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. J Am Vet Med Assoc 220: 1483, 2002.

Parenchymal Disorders

1. Rutherford A, Chung RT. Acute Liver Failure: Mechanisms of Hepatocyte Injury and Regeneration. *Semin Liver Dis* 2008;28:167-174.

2. van den Ingh T, van Winkle T, Cullen JM, Charles JA, Desmet VJ. Morphological classification of parenchymal disorders of the canine and feline liver. 2. Hepatocellular death, hepatitis and cirrhosis. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease*. Edinburgh: Saunders Elsevier, 2006;85-101.
3. Hartman EG, van den Ingh TSGAM, Rothuizen J. Clinical, pathological and serological features of spontaneous canine leptospirosis. An evaluation of the IgM- and IgG-specific ELISA. *Vet Immunol Immunopathol* 1986;13:261-291.
4. Poldervaart JH, Favier RP, Penning LC, et al. Primary hepatitis in dogs: a retrospective review (2002-2006). *J Vet Intern Med* 2009;23:72-80.
5. Cooper J, Webster CRL. Acute liver failure. *Comp Contin Educ* 2006;28:498 - 514.
6. Favier RP. Idiopathic hepatitis and cirrhosis in dogs. *Vet Clin North Am Small Anim Pract* 2009;39:481-488.
7. Center S. Interpretation of Liver Enzymes. *Vet Clin North Am Small Anim Pract* 2007;37:297-333.
8. Cullen JM. Summary of the World Small Animal Veterinary Association standardization committee guide to classification of liver disease in dogs and cats. *Vet Clin North Am Small Anim Pract* 2009;39:395-418.
9. Webster CRL, Cooper J. Therapeutic Use of Cytoprotective Agents in Canine and Feline Hepatobiliary Disease. *Vet Clin North Am Small Anim Pract* 2009;39:631-652.
10. Farrar ET, Washabau RJ, Saunders HM. Hepatic abscesses in dogs: 14 cases (1982-1994). *J Am Vet Med Assoc* 1996;208:243-247.

11. Schwarz LA, Penninck DG, Leveille-Webster C. Hepatic abscesses in 13 dogs: a review of the ultrasonographic findings, clinical data and therapeutic options. *Vet Radiol Ultrasound* 1998;39:357-365.
12. Sergeeff JS, Armstrong PJ, Bunch SE. Hepatic abscesses in cats: 14 cases (1985-2002). *J Vet Intern Med* 2004;18:295-300.
13. Zatelli A, Bonfanti U, Zini E, et al. Percutaneous drainage and alcoholization of hepatic abscesses in five dogs and a cat. *J Am Anim Hosp Assoc* 2005;41:34-38.
14. van Winkle T CJ, van den Ingh T, Charles JA, Desmet VJ. Morphological classification of parenchymal disorders of the canine and feline liver. 3. Hepatic abscesses and granulomas, hepatic metabolic storage disorders and miscellaneous conditions. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases*. Edinburgh: Saunders Elsevier, 2006;103 - 116.
15. Willard M. Inflammatory canine hepatic disease In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine*. 7th ed. St. Louis, Missouri: Saunders, Elsevier, 2010;1637-1642.
16. Center SA. Chronic hepatitis, cirrhosis, breed-specific hepatopathies, copper storage hepatopathy, suppurative hepatitis, granulomatous hepatitis, and idiopathic hepatic fibrosis. In: Guilford WG, Center SA, Strombeck DR, et al., eds. *Strombeck's Small Animal Gastroenterology*. 3rd ed. Philadelphia, PA: W.B. Saunders Company, 1996;705-765.
17. Lee WM. Drug-induced hepatotoxicity. *N Engl J Med* 2003;349:474-485.
18. Kleiner DE. The pathology of drug-induced liver injury. *Semin Liver Dis* 2009;29:364-372.
19. Chapman BL, Hendrick MJ, Washabau RJ. Granulomatous hepatitis in dogs: nine cases (1987-1990). *J Am Vet Med Assoc* 1993;203:680-684.

20. Navarro VJ, Senior JR. Drug-related hepatotoxicity. *N Engl J Med* 2006;354:731-739.
21. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. *J Vet Pharmacol Ther* 2004;27:129-138.
22. Hardy RM, Stevens JB, Stowe CM. Chronic progressive hepatitis in Bedlington terriers associated with elevated liver copper concentrations. *Minn Vet* 1975;15:13 - 24.
23. Twedt DC, Sternlieb I, Gilbertson SR. Clinical, morphologic, and chemical studies on copper toxicosis of Bedlington Terriers. *J Am Vet Med Assoc* 1979;175:269-275.
24. Thornburg LP, Shaw D, Dolan M, et al. Hereditary copper toxicosis in West Highland white terriers. *Vet Pathol* 1986;23:148-154.
25. Thornburg LP, Rottinghaus G, Dennis G, et al. The relationship between hepatic copper content and morphologic changes in the liver of West Highland White Terriers. *Vet Pathol* 1996;33:656-661.
26. Crawford MA, Schall WD, Jensen RK, et al. Chronic active hepatitis in 26 Doberman pinschers. *J Am Vet Med Assoc* 1985;187:1343-1350.
27. Mandigers PJ, van den Ingh TS, Bode P, et al. Association between liver copper concentration and subclinical hepatitis in Doberman Pinschers. *J Vet Intern Med* 2004;18:647-650.
28. Mandigers PJJ, van den Ingh TSGAM, Spee B, et al. Chronic hepatitis in Doberman Pinschers. A review. *Vet Q* 2004;26:99-106.
29. Andersson M, Sevelius E. Breed, sex and age distribution in dogs with chronic liver disease: a demographic study. *J Small Anim Pract* 1991;32:1-5.
30. Hardy RM. Chronic hepatitis in cocker spaniels - another syndrome? *American College of Veterinary Internal Medicine Forum* 1993;256 - 258.

31. Sevelius E, Andersson M, Jonsson L. Hepatic accumulation of alpha-1-antitrypsin in chronic liver disease in the dog. *J Comp Pathol* 1994;111:401-412.
32. Sevelius E. Diagnosis and prognosis of chronic hepatitis and cirrhosis in dogs. *J Small Anim Pract* 1995;36:521-528.
33. Sakai M, Sakamoto Y, Takemura A. Hepatopathy in seven American Cocker Spaniels. *J Vet Intern Med* 2007;21:653.
34. Haywood S, Rutgers HC, Christian MK. Hepatitis and copper accumulation in Skye Terriers. *Vet Pathol* 1988;25:408-414.
35. Webb CB, Twedt DC, Meyer DJ. Copper-associated liver disease in Dalmatians: a review of 10 dogs (1998-2001). *J Vet Intern Med* 2002;16:665-668.
36. Hoffmann G, van den Ingh TS, Bode P, et al. Copper-associated chronic hepatitis in Labrador Retrievers. *J Vet Intern Med* 2006;20:856-861.
37. Shih JL, Keating JH, Freeman LM, et al. Chronic hepatitis in Labrador Retrievers: Clinical presentation and prognostic factors. *J Vet Intern Med* 2007;21:33-39.
38. Smedley R, Mullaney T, Rumbleha W. Copper-associated hepatitis in Labrador retrievers. *Vet Pathol* 2009;46:484-490.
39. Bexfield NH, Scase TJ, Warman SM, et al. Chronic hepatitis in the English springer spaniel. *J Vet Intern Med* 2007;21:1435-1436.
40. Fuentealba C, Guest S, Haywood S, et al. Chronic hepatitis: a retrospective study in 34 dogs. *Can Vet J* 1997;38:365-373.
41. Strombeck DR, Miller LM, Harrold D. Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977-1985). *J Am Vet Med Assoc* 1988;193:1109-1113.

42. Raffan E, McCallum A, Scase TJ, et al. Ascites is a negative prognostic indicator in chronic hepatitis in dogs. *J Vet Intern Med* 2009;23:63-66.
43. Krawitt EL. Autoimmune hepatitis. *N Engl J Med* 2006;354:54-66.
44. Boomkens SY, Slump E, Egberink HF, et al. PCR screening for candidate etiological agents of canine hepatitis. *Vet Microbiol* 2005;108:49-55.
45. Gocke DJ, Morris TQ, Bradley SE. Chronic hepatitis in the dog: the role of immune factors. *J Am Vet Med Assoc* 1970;156:1700-1705.
46. Rakich PM, Prasse KW, Lukert PD, et al. Immunohistochemical detection of canine adenovirus in paraffin sections of liver. *Vet Pathol* 1986;23:478-484.
47. Chouinard L, Martineau D, Forget C, et al. Use of polymerase chain reaction and immunohistochemistry for detection of canine adenovirus type 1 in formalin-fixed, paraffin-embedded liver of dogs with chronic hepatitis or cirrhosis. *J Vet Diagn Invest* 1998;10:320-325.
48. Jarrett WF, O'Neil BW. A new transmissible agent causing acute hepatitis, chronic hepatitis and cirrhosis in dogs. *Vet Rec* 1985;116:629-635.
49. Jarrett WF, O'Neil BW, Lindholm I. Persistent hepatitis and chronic fibrosis induced by canine acidophil cell hepatitis virus. *Vet Rec* 1987;120:234-235.
50. Bishop L, Strandberg JD, Adams RJ, et al. Chronic active hepatitis in dogs associated with leptospires. *Am J Vet Res* 1979;40:839-844.
51. Adamus C, Buggin-Daubie M, Izembart A, et al. Chronic hepatitis associated with leptospiral infection in vaccinated beagles. *J Comp Pathol* 1997;117:311-328.
52. Rallis T, Day MJ, Saridomichelakis MN, et al. Chronic hepatitis associated with canine leishmaniosis (*Leishmania infantum*): a clinicopathological study of 26 cases. *J Comp Pathol* 2005;132:145-152.

53. Gillespie TN, Washabau RJ, Goldschmidt MH, et al. Detection of *Bartonella henselae* and *Bartonella clarridgeiae* DNA in hepatic specimens from two dogs with hepatic disease. *J Am Vet Med Assoc* 2003;222:47-51, 35.
54. Hoffmann G. Copper-associated liver diseases. *Vet Clin North Am Small Anim Pract* 2009;39:489-511.
55. Webb C, Twedt D. Oxidative stress and liver disease. *Vet Clin North Am Small Anim Pract* 2008;38:125-135, v.
56. Thornburg LP. A perspective on copper and liver disease in the dog. *J Vet Diagn Invest* 2000;12:101-110.
57. Rolfe DS, Twedt DC. Copper-associated hepatopathies in dogs. *Vet Clin North Am Small Anim Pract* 1995;25:399-417.
58. Haynes JS, Wade PR. Hepatopathy associated with excessive hepatic copper in a Siamese cat. *Vet Pathol* 1995;32:427-429.
59. Meertens NM, Bokhove CAM, Ingh TSGAMvd. Copper-associated chronic hepatitis and cirrhosis in a European Shorthair cat. *Vet Pathol* 2005;42:97-100.
60. Thornburg LP, Rottinghaus G, McGowan M, et al. Hepatic copper concentrations in purebred and mixed-breed dogs. *Vet Pathol* 1990;27:81-88.
61. Sternlieb I, Twedt DC, Johnson GF, et al. Inherited copper toxicity of the liver in Bedlington terriers. *Proc R Soc Med* 1977;70 Suppl 3:8-9.
62. Hill TL, Breitschwerdt EB, Cecere T, et al. Concurrent hepatic copper toxicosis and Fanconi's syndrome in a dog. *J Vet Intern Med* 2008;22:219-222.
63. Appleman EH, Cianciolo R, Mosenco AS, et al. Transient acquired fanconi syndrome associated with copper storage hepatopathy in 3 dogs. *J Vet Intern Med* 2008;22:1038-1042.

64. van De Sluis B, Rothuizen J, Pearson PL, et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. *Hum Mol Genet* 2002;11:165-173.
65. Klomp AE, van de Sluis B, Klomp LW, et al. The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis. *J Hepatol* 2003;39:703-709.
66. Spee B, Arends B, van den Ingh TS, et al. Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver diseases in dogs. *J Vet Intern Med* 2006;20:1085-1092.
67. van den Ingh TS, Rothuizen J, Cupery R. Chronic active hepatitis with cirrhosis in the Doberman pinscher. *Vet Q* 1988;10:84-89.
68. Johnston AN, Center SA, McDonough SP, et al. Hepatic copper concentrations in Labrador retrievers with and without chronic hepatitis (1980-2008): an emerging syndrome or over-supplementation? *J Vet Intern Med* 2009:760-761.
69. Schultheiss PC, Bedwell CL, Hamar DW, et al. Canine liver iron, copper, and zinc concentrations and association with histologic lesions. *J Vet Diagn Invest* 2002;14:396-402.
70. Dayrell-Hart B, Steinberg SA, VanWinkle TJ, et al. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989). *J Am Vet Med Assoc* 1991;199:1060-1066.
71. Bunch SE. Hepatotoxicity associated with pharmacologic agents in dogs and cats. *Vet Clin North Am* 1993;23:659-669.
72. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. *J Vet Intern Med* 2004;18:75-80.
73. MacPhail CM, Lappin MR, Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. *J Am Vet Med Assoc* 1998;212:1895-1901.

74. Kroeze EJ, Zentek J, Edixhoven-Bosdijk A, et al. Transient erythropoietic protoporphyria associated with chronic hepatitis and cirrhosis in a cohort of German shepherd dogs. *Vet Rec* 2006;158:120-124.
75. Speeti M, Stahls A, Meri S, et al. Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis. *Vet Immunol Immunopathol* 2003;96:1-12.
76. Watson PJ. Chronic hepatitis in dogs: a review of current understanding of the aetiology, progression, and treatment. *Vet J* 2004;167:228-241.
77. Andersson M, Sevelius E. Circulating autoantibodies in dogs with chronic liver disease. *J Small Anim Pract* 1992;33:389-394.
78. Weiss DJ, Armstrong PJ, Mruthyunjaya A. Anti-liver membrane protein antibodies in dogs with chronic hepatitis. *J Vet Intern Med* 1995;9:267-271.
79. Boisclair J, Dore M, Beauchamp G, et al. Characterization of the inflammatory infiltrate in canine chronic hepatitis. *Vet Pathol* 2001;38:628-635.
80. Sakai M, Otani I, Ishigaki K, et al. Phenotypic analysis of hepatic T lymphocytes in a dog with chronic hepatitis. *J Vet Med Sci* 2006;68:1219-1221.
81. Thornburg LP. Histomorphological and immunohistochemical studies of chronic active hepatitis in Doberman Pinschers. *Vet Pathol* 1998;35:380-385.
82. Sakai M, Otani I, Watari T, et al. Phenotypic analysis of hepatic lymphocytes from healthy dogs. *J Vet Med Sci* 2003;65:157-159.
83. Sevelius E, Andersson M. Serum protein electrophoresis as a prognostic marker of chronic liver disease in dogs. *Vet Rec* 1995;137:663-667.

84. Johnston AN, Center SA, McDonough SP, et al. Influence of biopsy specimen size, tissue fixation, and assay variation on copper, iron, and zinc concentrations in canine livers. *Am J Vet Res* 2009;70:1502-1511.
85. Leveille-Webster CR, Center SA. Chronic hepatitis: Therapeutic considerations In: Bonagura JD, ed. *Current Veterinary Therapy*. CVT XII ed. Philadelphia, PA: W. B. Saunders Co., 1995;749-756.
86. Twedt DC. Diagnosis and management of copper associated liver disease in dogs. *Eur J Comp Gastro* 1997;2:7-12.
87. Mandigers PJ, van den Ingh TS, Bode P, et al. Improvement in liver pathology after 4 months of D-penicillamine in 5 doberman pinschers with subclinical hepatitis. *J Vet Intern Med* 2005;19:40-43.
88. Seguin MA, Bunch SE. Iatrogenic copper deficiency associated with long-term copper chelation for treatment of copper storage disease in a Bedlington Terrier. *J Am Vet Med Assoc* 2001;218:1593-1597, 1580.
89. Brewer GJ, Dick RD, Schall W, et al. Use of zinc acetate to treat copper toxicosis in dogs. *J Am Vet Med Assoc* 1992;201:564-568.
90. Hoffmann G, Jones PG, Biourge V, et al. Dietary management of hepatic copper accumulation in Labrador retrievers. *J Vet Intern Med* 2009;23:957-963.
91. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. *Am J Vet Res* 2002;63:1187-1197.
92. Ubbink GJ, Van den Ingh TS, Yuzbasiyan-Gurkan V, et al. Population dynamics of inherited copper toxicosis in Dutch Bedlington terriers (1977-1997). *J Vet Intern Med* 2000;14:172-176.

93. Yuzbasiyan-Gurkan V, Blanton SH, Cao Y, et al. Linkage of a microsatellite marker to the canine copper toxicosis locus in Bedlington terriers. *Am J Vet Res* 1997;58:23-27.
94. Haywood S, Fuentealba IC, Kemp SJ, et al. Copper toxicosis in the Bedlington terrier: a diagnostic dilemma. *J Small Anim Pract* 2001;42:181-185.
95. Speeti M, Eriksson J, Westermarck E. Some new aspects of the role of copper in doberman hepatitis. *Euro J Vet Path* 1999;5:51-56.
96. Mandigers PJJ, Senders T, Rothuizen J. Morbidity and mortality in 928 Doberman Pinschers born in the Netherlands between 1993 and 1999. *Vet Rec* 2006;158:226-229.
97. Mandigers PJ, Bode P, van Wees AM, et al. Hepatic (64)Cu excretion in Dobermanns with subclinical hepatitis. *Res Vet Sci* 2007;83:204-209.
98. Spee B, Mandigers P, Arends B, et al. Differential expression of copper-associated and oxidative stress related proteins in a new variant of copper toxicosis in Doberman pinschers. *Comp Hepatol* 2005;4:3.
99. Speeti M, Ihantola M, Westermarck E. Subclinical versus clinical hepatitis in the dobermann: evaluation of changes in blood parameters. *J Small Anim Pract* 1996;37:465-470.
100. Speeti M, Eriksson J, Saari S, et al. Lesions of subclinical doberman hepatitis. *Vet Pathol* 1998;35:361-369.
101. Thornburg LP, Crawford SJ. Liver disease in West Highland white terriers. *Vet Rec* 1986;118:110.
102. Noaker LJ, Washabau RJ, Detrisac CJ, et al. Copper associated acute hepatic failure in a dog. *J Am Vet Med Assoc* 1999;214:1502-1506, 1495.
103. Brown DL, Van Winkle T, Cecere T, et al. Congenital hepatic fibrosis in 5 dogs. *Vet Pathol* 2010;47:102-107.

104. Rutgers HC, Haywood S, Kelly DF. Idiopathic hepatic fibrosis in 15 dogs. *Vet Rec* 1993;133:115-118.
105. Zandvliet MM, Szatmari V, van den Ingh T, et al. Acquired portosystemic shunting in 2 cats secondary to congenital hepatic fibrosis. *J Vet Intern Med* 2005;19:765-767.
106. Guo J, Friedman SL. Hepatic fibrogenesis. *Semin Liver Dis* 2007;27:413-426.
107. Mekonnen GA, Ijzer J, Nederbragt H. Tenascin-C in chronic canine hepatitis: immunohistochemical localization and correlation with necro-inflammatory activity, fibrotic stage, and expression of alpha-smooth muscle actin, cytokeratin 7, and CD3+ cells. *Vet Pathol* 2007;44:803-813.
108. Spee B, Arends B, van den Ingh TSGAM, et al. Transforming growth factor beta-1 signalling in canine hepatic diseases: new models for human fibrotic liver pathologies. *Liver International* 2006;26:716-725.
109. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. *J Hepatol* 2004;40:860-867.
110. Jensen AL, Nielsen OL. Chronic hepatitis in three young standard poodles. *J Vet Med A* 1991;38:194-197.
111. van den Ingh TS, Rothuizen J. Lobular dissecting hepatitis in juvenile and young adult dogs. *J Vet Intern Med* 1994;8:217-220.
112. Bennett AM, Davies JD, Gaskell CJ, et al. Lobular dissecting hepatitis in the dog. *Vet Pathol* 1983;20:179-188.
113. Center SA. Hepatobiliary Infections In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 3rd ed. St. Louis, Missouri: Saunders Elsevier, 2006;912 - 935.

114. Greene CE. Infectious Canine Hepatitis and Canine Acidophil Cell Hepatitis In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 3rd ed. St. Louis, Missouri: Elsevier Saunders, 2006;41 - 47.
115. Gocke DJ, Preisig R, Morris TQ, et al. Experimental viral hepatitis in the dog: production of persistent disease in partially immune animals. *J Clin Invest* 1967;46:1506-1517.
116. Decaro N, Martella V, Buonavoglia C. Canine adenoviruses and herpesvirus. *Vet Clin North Am Small Anim Pract* 2008;38:799-814, viii.
117. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963 - 2008. *J Fel Med Surg* 2009;11:225-258.
118. Greene CE, Sykes JE, Brown CA, et al. Leptospirosis In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 3rd ed. St. Louis, Missouri: Saunders Elsevier, 2006;402 - 417.
119. Goldstein RE, Lin RC, Langston CE, et al. Influence of infecting serogroup on clinical features of leptospirosis in dogs. *J Vet Intern Med* 2006;20:489-494.
120. Geisen V, Stengel C, Brem S, et al. Canine leptospirosis infections - clinical signs and outcome with different suspected *Leptospira* serogroups (42 cases). *J Small Anim Pract* 2007;48:324-328.
121. Harken KR. Leptospirosis In: Bonagura JD, ed. *Kirk's Current Veterinary Therapy*. XIV ed. St. Louis, Missouri: Saunders Elsevier, 2009;1237 - 1240.
122. Greenlee JJ, Bolin CA, Alt DP, et al. Clinical and pathologic comparison of acute leptospirosis in dogs caused by two strains of *Leptospira kirschneri* serovar grippotyphosa. *Am J Vet Res* 2004;65:1100-1107.
123. Jones BR, Greene CE. Tyzzer's Disease In: Greene CE, ed. *Infectious Diseases of the Dog and Cat*. 3rd ed. St. Louis, Missouri: Saunders Elsevier, 2006;362 - 363.

124. Taboada J, Meyer DJ. Cholestasis associated with extrahepatic bacterial infection in five dogs. *J Vet Intern Med* 1989;3:216-221.
125. Moseley RH. Sepsis and cholestasis. *Clin Liver Dis* 2004;8:83-94.
126. Scherk MA, Center SA. Toxic, metabolic, infectious, and neoplastic liver diseases In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine*. 7th ed. St. Louis, Missouri: Saunders, Elsevier, 2010;1672 - 1679.
127. Navarro VJ. Herbal and dietary supplement hepatotoxicity. *Semin Liver Dis* 2009;29:373-382.
128. Center SA. Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. *Vet Clin North Am Small Anim Pract* 2004;34:67-172.
129. Flatland B. Botanicals, vitamins, and minerals and the liver: Therapeutic applications and potential toxicities. *Comp Contin Educ* 2003;25:514 - 524.
130. Freeman LM, Abood SK, Fascetti AJ, et al. Disease prevalence among dogs and cats in the United States and Australia and proportions of dogs and cats that receive therapeutic diets or dietary supplements. *J Am Vet Med Assoc* 2006;229:531-534.
131. Loftin EG, Herold LV. Therapy and outcome of suspected alpha lipoic acid toxicity in two dogs. *J Vet Emerg Crit Care* 2009;19:501-506.
132. Harkin KR, Cowan LA, Andrews GA, et al. Hepatotoxicity of stanozolol in cats. *J Am Vet Med Assoc* 2000;217:681-684.
133. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. *Hepatology* 2008;47:2003-2009.

134. Kraus MS, Thomason JD, Fallaw TL, et al. Toxicity in Doberman Pinchers with ventricular arrhythmias treated with amiodarone (1996-2005). *J Vet Intern Med* 2009;23:1-6.
135. Watkins PB. Idiosyncratic liver injury: Challenges and approaches. *Toxicol Pathol* 2005;33:1-5.
136. Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. *Hepatology* 2010;51:615-620.
137. Jacobs G, Calvert C, Kraus M. Hepatopathy in 4 dogs treated with amiodarone. *J Vet Intern Med* 2000;14:96-99.
138. Dereszynski DM, Center SA, Randolph JF, et al. Clinical and clinicopathologic features of dogs that consumed foodborne hepatotoxic aflatoxins: 72 cases (2005-2006). *J Am Vet Med Assoc* 2008;232:1329-1337.
139. Hall K. Toxicosis treatments In: Bonagura JD, Twedt D, eds. *Kirk's Current Veterinary Therapy*. XIV ed. St. Louis, MO: Saunders Elsevier, 2009;112-116.
140. Avizeh R, Najafzadeh H, Razijalali M, et al. Evaluation of prophylactic and therapeutic effects of silymarin and N-acetylcysteine in acetaminophen-induced hepatotoxicity in cats. *J Vet Pharmacol Ther* 2010;33:95-99.
141. Vogel G TB, Trost W, Mengs U. Protection by silibinin against *Amanita phalloides* intoxication in beagles. *Toxicol Appl Pharmacol* 1984;73:355-362.
142. Taylor NS, Dhupa N. Acetaminophen toxicity in cats and dogs. *Comp Cont Educ* 2000;22:160 -170.
143. Wallace KP, Center SA, Hickford FH, et al. S-adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog. *J Am Anim Hosp Assoc* 2002;38:246-254.

144. McConkey SE, Grant DM, Cribb AE. The role of para-aminophenol in acetaminophen-induced methemoglobinemia in dogs and cats. *J Vet Pharmacol Ther* 2009;32:585-595.
145. Webb CB, Twedt DC, Fettman MJ, et al. S-adenosylmethionine (SAME) in a feline acetaminophen model of oxidative injury. *J Feline Med Surg* 2003;5:69-75.
146. Greene C, Hartmann K, Calpin J. Antimicrobial drug formulary In: Greene CE, ed. *Infectious Disease in the Dog and Cat*. 3rd ed. St. Louis, Missouri: Saunders Elsevier, 2006;1186 - 1333.
147. Favrot C, Reichmuth P, Olivry T. Treatment of canine atopic dermatitis with azathioprine: a pilot study. *Vet Rec* 2007;160:520-521.
148. Starzl TE, Marchioro TL, Porter KA, et al. Factors determining short- and long-term survival after orthotopic liver homotransplantation in the dog. *Surgery* 1965;58:131-155.
149. Tolman KG. Hepatotoxicity of non-narcotic analgesics. *Am J Med* 1998;105:13S-19S.
150. Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. *Vet Clin North Am Small Anim Pract* 2008;38:1243-1266, vi.
151. Center SA, Elston TH, Rowland PH, et al. Fulminant hepatic failure associated with oral administration of diazepam in 11 cats. *J Am Vet Med Assoc* 1996;209:618-625.
152. Hughes D, Moreau RE, Overall KL, et al. Acute hepatic necrosis and liver failure associated with benzodiazepine therapy in six cats, 1986-1995. *J Vet Emerg Crit Care* 1996;6:13-20.
153. Schaer M, Ginn PE. Iatrogenic Cushing's syndrome and steroid hepatopathy in a cat. *J Am Anim Hosp Assoc* 1999;35:48-51.
154. Fernandez NJ, Kidney BA. Alkaline phosphatase: beyond the liver. *Vet Clin Pathol* 2007;36:223-233.

155. Hosoya K, Lord LK, Lara-Garcia A, et al. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine). *Vet Comp Oncol* 2009;7:244-255.
156. Hammond GM, Kent MS, Irish AM, et al. Denamarin® for the prevention of lomustine (CCNU) induced hepatotoxicity in tumor bearing dogs: Interim analysis. *J Vet Intern Med* 2009;23:744.
157. Muller PB, Taboada J, Hosgood G, et al. Effects of long-term phenobarbital treatment on the liver in dogs. *J Vet Intern Med* 2000;14:165-171.
158. March PA, Hillier A, Weisbrode SE, et al. Superficial necrolytic dermatitis in 11 dogs with a history of phenobarbital administration (1995-2002). *J Vet Int Med* 2004;18:65-74.
159. Trepanier LA, Danhof R, Toll J, et al. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. *J Vet Int Med* 2003;17:647-652.
160. Schulz B, Hupfauer S, Hartmann K. Investigation of doxycycline-related side effects in dogs. *J Vet Intern Med* 2009;23:695.
161. Stenske KA, Smith JR, Newman SJ, et al. Aflatoxicosis in dogs and dealing with suspected contaminated commercial foods. *J Am Vet Med Assoc* 2006;228:1686-1691.
162. Tegzes JH, Puschner B. Toxic mushrooms. *Vet Clin North Am Small Anim Pract* 2002;32:397-407.
163. Puschner B, Rose HH, Filigenzi MS. Diagnosis of Amanita toxicosis in a dog with acute hepatic necrosis. *J Vet Diagn Invest* 2007;19:312-317.
164. DeVries SE, Galey FD, Namikoshi M, et al. Clinical and pathologic findings of blue-green algae (*Microcystis aeruginosa*) intoxication in a dog. *J Vet Diagn Invest* 1993;5:403-408.
165. Albretsen JC, Khan SA, Richardson JA. Cycad palm toxicosis in dogs: 60 cases (1987-1997). *J Am Vet Med Assoc* 1998;213:99-101.

166. Senior DF, Sundlof SF, Buergelt CD, et al. Cycad Intoxication in the Dog. *J Am Anim Hosp Assoc* 1985;21:103-109.

167. Ferguson D, Crowe M, Acierno M, et al. Cycad intoxication in dogs: survival and prognostic indicators. *J Vet Intern Med* 2010;24:719.

168. Piscitelli CM, Dunayer EK, M. A. Xylitol toxicity in dogs. *Comp Contin Educ* 2010:E1-E4.

169. Dunayer EK, Gwaltney-Brant SM. Acute hepatic failure and coagulopathy associated with xylitol ingestion in eight dogs. *J Am Vet Med Assoc* 2006;229:1113-1117.

Vascular Disorders

1. Maddison JE. Hepatic encephalopathy. Current concepts of the pathogenesis. *J Vet Intern Med* 1992;6:341-353

2. Rothuizen J. Portosystemic hepatic encephalopathy related with congenital and acquired hepatopathies in the dog. *Adv Vet Sci Comp Med* 1993;37:403-415.

3. Marretta SM, Pask AJ, Greene RW, Liu S. Urinary calculi associated with portosystemic shunts in six dogs. *J Am Vet Med Assoc* 1981;178(2):133-137.

4. Aronson LR, Gacad RC, Kaminsky-Russ, Gregory CR, Mullen KD. Endogenous benzodiazepine activity in the peripheral and portal blood of dogs with congenital portosystemic shunts. *Vet Surg* 1997;26:189-194.

5. Wess G, Unterer S, Haller M, Hasler A, Reusch C, Glaus T. Recurrent fever as the only or predominant clinical sign in four dogs and one cat with congenital portosystemic vascular anomalies. *Schweiz Arch Tierheilkd* 2003;145(8):363-368.

6. Wessmann A, Volk HA, Shelton GD, Chandler KE, Baines S, Cappello R. Portosystemic shunt associated with severe episodic weakness. *J Vet Intern Med* 2006;20:1042-1044.

7. Levy JE, Bunch SE, Komtebedde J. Feline portosystemic vascular shunts. 743-749. in Bonagura J (ed) Kirk`s Current Veterinary Therapy XII 1995 Saunders
8. Berger B, WhitingPG, Breznock EM, Bruhl-Day R, Moore PF. Congenital feline portosystemic shunts. J Am Vet Med Assoc 1986;188(5):517-521.
9. Schunk CM. Feline portosystemic shunts. Semin Vet Med Surg Small Anim 1997;12:45-50.
10. Szatmári V, Rothuizen J, van den Ingh TSGAM, et al. Ultrasonographic findings in dogs with hyperammonemia: 90 cases (2000-2002). J Am Vet Med Assoc 2004;224:717-727.
11. Bunch SE, Johnson SE, Cullen JM. Idiopathic noncirrhotic portal hypertension in dogs: 33 cases (1982-1998). J Am Vet Med Assoc 2001;218:392-399.
12. Van den Ingh TSGAM, Rothuizen J, Meyer HP. Portal hypertension associated with primary hypoplasia of the hepatic portal vein in dogs. Vet Rec 1995;137:424-427.
13. Cullen JM, van den Ingh TSGAM, Bunch SE, Rothuizen J, Washabau RJ, Desmet VJ. Morphological classification of circulatory disorders of the canine and feline liver. In WSAVA Liver Standardization Group. WSAVA Standards for clinical and histological diagnosis of canine and feline liver diseases. pp 41-59. Saunders Elsevier, 2006
14. Schermerhorn T, Center SA, Dykes NL, Rowland PH, Yeager AE, Erb HN, Oberhansley K, Bonda M. Characterization of hepatoportal microvascular dysplasia in a kindred of cairn terriers. J Vet Intern Med 1996;10:219-230.
15. Szatmári V, Rothuizen J. Ultrasonographic identification and characterization of congenital portosystemic shunts and portal hypertensive disorders in dogs and cats. In WSAVA Liver Standardization Group. WSAVA Standards for clinical and histological diagnosis of canine and feline liver diseases. pp 15-39. Saunders Elsevier, 2006
16. Kalt DJ, Stump JE. Gross anatomy of the canine portal vein. Anat Histol Embryol 1993;22:191-197.

17. Johnson SE. Portal hypertension Part I. Pathophysiology and clinical consequences. *Comp Cont Edu Pract Vet Small Anim* 1987;9(7):741-748.
18. Szatmári V, Rothuizen J, van Sluijs FJ, van den Ingh TSGAM, Voorhout G. Ultrasonographic evaluation of partially attenuated congenital extrahepatic portosystemic shunts in 14 dogs. *Vet Rec* 2004;155:448-456.
19. Bosje JT, van den Ingh TSGAM, van der Linde-Sipman JS. Polycystic kidney and liver disease in cats. *Vet Quart* 1998;20:136-140.
20. Zandvliet MMJM, Szatmári V, van den Ingh TSGAM, Rothuizen J. Acquired portosystemic shunting in 2 cats secondary to congenital hepatic fibrosis. *J Vet Intern Med* 2005;19:765-767.
21. Szatmári V, van den Ingh TSGAM, Fenyves B, Sótónyi P, Kótai I, Petrászi Z, Vörös K. Portal hypertension in a dog due to circumscribed fibrosis of the wall of the extrahepatic portal vein. *Vet Rec* 2002;150:602-605.
22. McConnell JF, Sparkes AH, Ladlow J, Doust R, Davies S. Ultrasonographic diagnosis of unusual portal vascular abnormalities in two cats. *J Small Anim Pract* 2006;47:338-343.
23. Van Winkle, Bruce E. Thrombosis of the portal vein in eleven dogs. *Vet Pathol* 1993;30:28-35.
24. Flowers JR, Hammerberg B, Wood SL, et al. Heterobilharzia americana infection in a dog. *J Am Vet Med Assoc* 2002;220:193-196.
25. Favier RP, Szatmári V, Rothuizen J. Multiple congenital portal vein anomalies in a dog. *Vet Rec* 2004;154:604-605.
26. Szatmári V, van Sluijs FJ, Rothuizen J, Voorhout G. Intraoperative ultrasonography of the portal vein during attenuation of intrahepatic portocaval shunts in dogs. *J Am Vet Med Assoc* 2003;222:1086-1092.

27. Vitums A. Portosystemic communications in the dog. *Acta Anat* 1959;39:271-299.
28. Meyer HP, Rothuizen J. Nutritional aspects of the management of chronic hepatic encephalopathy. *Eur J Comp Gastroenterol* 1998;3(2):13-18.
29. Zeneroli ML, Baraldi M, Ventura E, Vezzelli C, Tofanetti O, Germini M, Casciarri I. Alterations of GABA-A and dopamine D-2 brain receptors in dogs with portal-systemic encephalopathy. *Life Sci* 1991;48(1):37-50.
30. Snowden NJ, Helyar CV, Platt SR, Penderis J. Clinical presentation and management of moxidectin toxicity in two dogs. *J Small Anim Pract* 2006;47:620-624.
31. Matushek KJ, Bjorling D, Mathews K. Generalized motor seizures after portosystemic shunt ligation in dogs: five cases (1981-1988). *J Am Vet Med Assoc* 1990;196(12):2014-2017.
32. Center SA. Nutritional support for dogs and cats with hepatobiliary disease. *J Nutr* 1998;128:2733 S-2746 S.
33. Meyer HP, Chamuleau RAFM, Legemate DA, Mol JA, Rothuizen J. Effects of a branched chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs. *Metabol Brain Dis* 1999;14(2)103-115.
34. Holt DE, Washabau RJ, Djali S, Dayrell-Hart B, Drobatz KJ, Heyes MP, Robinson MB. Cerebrospinal fluid glutamine, tryptophan, and tryptophan metabolite concentrations in dogs with portosystemic shunts. *Am J Vet Res* 2002;63:1167-1171.
35. Fischer RA, Baldessarini RJ. False neurotransmitter in hepatic coma. *Lancet* 1971;2:75-80.
36. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. *Gastroenterology* 1980;78:663-670.
37. Als-Nielsen B, Glud LL, Glud C. Dopaminergic agonists for hepatic encephalopathy. *Cochrane Database Syst Rev* 2004;4:CD003047.

38. Felipo V, Butterworth RF. Neurobiology of ammonia. *Progr Neurobiol* 2002;67:259-279.
39. Basile AS. Direct and indirect enhancement of GABAergic neurotransmission by ammonia: implications for the pathogenesis of hyperammonemic syndromes. *Neurochemistry International* 2002;41:115-122.
40. Norenberg MD, Neary JT, Bender AS, Dombro RS. Hepatic encephalopathy: a disorder in glial-neuronal communications. *Progr Brain Res* 1992;94:261-269.
41. Maddison JE, Watson WE, Johnston GA. L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. *Metab Brain Dis* 1995;10(2):135-141.
42. Norenberg MD, Rama Rao KV, Jayakumar RA. Mechanisms of ammonia-induced astrocyte swelling. *Metab Brain Dis* 2005;20:303-318.
43. Rothuizen J, Mol JA. The pituitary-Adrenocortical system in canine hepato-encephalopathy. *Front Horm Res* 1987;17:28-36.
44. Meyer HP, Rothuizen J. Increased free cortisol in plasma of dogs with portosystemic encephalopathy (PSE). *Dom Anim Endocrin* 1994;11(4):317-322.
45. Rothuizen J, Biewenga WJ, Mol JA. Chronic glucocorticoid excess and impaired osmoregulation of vasopressin release in dogs with hepatic encephalopathy. *Dom Anim Endocrin* 1995;12:13-24.
46. Sterczer A, Meyer HP, van Sluijs FJ, Rothuizen J. Fast resolution of hypercortisolism in dogs with portosystemic encephalopathy after surgical shunt closure. *Research in Veterinary Science* 1998;66:63-67.
47. Cohen M, Post GS. Water transport in the kidney and nephrogenic diabetes insipidus. *J Vet Intern Med* 2002;16:510-517.

48. Rothuizen J, de Kok Y, Slob A, Mol JA. GABAergic inhibition of the pituitary release of adrenocorticotropin and α -melanotropin is impaired in dogs with hepatic encephalopathy. *Dom Anim Endocrin* 1996;13(1):59-68.
49. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target specificity is enzyme, not receptor, mediated. *Science* 1988;242(4878):583-585.
50. Marples D, Frøkiær J, Dørup J, Knepper MA, Nielsen S. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. *J Clin Invest* 1996;97:1960-1968.
51. Martin PT, Schrier RW. Role of aquaporin-2 water channels in urinary concentration and dilution defects. *Kidney International* 1998;53(Suppl 65):S-57–S-62.
52. Cuypers MD, Grooters AM, Williams J, Partington BP. Renomegaly in dogs and cats. Part I. Differential diagnosis. *Comp Cont Ed Pract Vet* 1997;19:1019-1032.
53. Deppe TA, Center SA, Simpson KW, Erb HN, Randolph JF, Dykes NL, Yeager AE, Reynolds AJ. Glomerular filtration rate and renal volume in dogs with congenital portosystemic vascular anomalies before and after surgical ligation. *J Vet Intern Med* 1999;13:465-471.
54. Lamb CR, White RN. Morphology of congenital portocaval shunts in dogs and cats. *Vet Rec* 1998;142:55-60.
55. Hunt GB, Bellenger CR, Borg R, Youmans KR, Tisdall PLC, Malik R. Congenital interruption of the portal vein and caudal vena cava in dogs: six case reports and a review of the literature. *Vet Surg* 1998;27:203-215.
56. Lohse CL, Suter PF. Functional closure of the ductus venosus during early postnatal life in the dog. *Am J Vet Res* 1977;38(6):839-844.

57. Payne JT, Martin RA, Constantinescu GM. The anatomy and embriology of portosystemic shunts in dogs and cats. *Sem Vet Med Surg Small Anim* 1990;5:76-82.
58. Lamb CR, Forster-van Hijfte MA, White RN, et al. Ultrasonographic diagnosis of congenital portosystemic shunt in 14 cats. *J Small Anim Pract* 1996;37:205-209.
59. Meyer HP, Rothuizen J, Ubbink GJ, van den Ingh TSGAM. Increasing incidence of hereditary intrahepatic portosystemic shunts in Irish wolfhounds in the Netherlands (1984 to 1992). *Vet Rec* 1995;136:13-16.
60. Tobias KM. Determination of inheritance of single congenital portosystemic shunts in Yorkshire terriers. *J Am Anim Hosp Assoc* 2003;39:385-389.
61. Van Straten G, Leegwater M, de Vries WE, van den Brom WE, Rothuizen J. Inherited congenital extrahepatic portosystemic shunts in cairn terriers. *J Vet Intern Med* 2005;19:321-324.
62. Helps CR, Tasker S, Barr FJ, Wills SJ, Gruffydd-Jones T. Detection of the single nucleotide polymorphism causing feline autosomal-dominant polycystic kidney disease in Persians from the UK using a novel real-time PCR assay. *Molecular Cellular Probes* 2007;21:31-34.
63. Gerritzen-Bruning MJ, van den Ingh TSGAM, Rothuizen J. Diagnostic value of fasting plasma ammonia and plasma bile acid concentrations in the identification of portosystemic shunting in dogs. *J Vet Intern Med* 2006;20:13-19.
64. Strombeck DP, Meyer DJ, Freedland RA. Hyperammonemia due to a urea cycle enzyme deficiency. *J Am Vet Med Assoc* 1975;166:1109-1111.
65. Washizu T, Washizu M, Zhang C, Matsumoto I, Sawamura M, Suzuki T. A suspected case of ornithine transcarbamylase deficiency in a cat. *J Vet Med Sci* 2004;66(6):701-703.

66. Meyer HP, Rothuizen J, Tiemessen I, van den Brom WE, van den Ingh TSGAM. Transient metabolic hyperammonaemia in young Irish wolfhounds. *Vet Rec* 1996;138:105-107.
67. Hall JA, Allen TA, Fettman MJ. Hyperammonemia associated with urethral obstruction in a dog. *J Am Vet Med Assoc* 1987;191:1116-1118.
68. Morris JG, Rogers QR. Ammonia intoxication in the near-adult cat as a result of a dietary deficiency of arginine. *Science* 1978;199:431-432.
69. Vaden SL, Wood PA, Ledley FD, Cornwell PD, Miller RT, Page R. Cobalamin deficiency associated with methylmalonic acidemia in a cat. *J Am Vet Med Assoc* 1992;200:1101-1103.
70. Lobetti RG, Miller DB, Dippenaar T. Transient hyperammonemia in an adult German shepherd dog. *Tydkr S Afr Vet Ver* 1997;68(2):66-68.
71. Center SA, Baldwin BH, de Lahunta A, Dietze AE, Tennant BC. Evaluation of bile acid concentrations for the diagnosis of portosystemic venous anomalies in the dog and cat. *J Am Vet Med Assoc* 1985;186(10):1090-1094.
72. Krotscheck U, Adin CA, Hunt GB, Kyles AE, Erb HN. Epidemiologic factors associated with the anatomic location of intrahepatic portosystemic shunts in dogs. *Vet Surg* 2007;36:31-36.
73. Tobias KM, Rohrbach BW. Association of breed with the diagnosis of congenital portosystemic shunts in dogs: 2400 cases (1980-2002). *J Am Vet Med Assoc* 2003;223:1636-1639.
74. Meyer DJ, Strombeck DR, Stone EA, Zenoble RD, Buss DD. Ammonia tolerance test in clinically normal dogs and in dogs with portosystemic shunts. *J Am Vet Med Assoc* 1978;173:377-379.
75. Rothuizen J, van den Ingh TSGAM. Rectal ammonia tolerance test in the evaluation of portal circulation in dogs with liver disease. *Res Vet Sci* 1982;33:22-25.
76. Walker MC, Hill RC, Guilford WG, Scott KC, Jones GL, Buergelt CD. Postprandial venous ammonia concentration in the diagnosis of hepatobiliary disease in dogs. *J Vet Intern Med* 2001;15:463-466.

77. Schaeffer MC, Rogers QR, Buffington CA, Wolfe BM, Strombeck DR. Long-term biochemical and physiologic effects of surgically placed portocaval shunts in dogs. *Am J Vet Res* 1986;47(2):346-355.
78. Center SA. Liver function tests in the diagnosis of portosystemic vascular anomalies. *Sem Vet Med Surg Small Anim* 1990;5:94-99.
79. Center SA, ManWarren T, Slater MR, Wilentz E. Evaluation of twelve-hour preprandial and two-hour postprandial serum bile acids disease in dogs. *J Am Vet Med Assoc* 1991;199:217-227.
80. Meyer DJ, Harvey JW. Hematologic changes associated with serum and hepatic iron alterations in dogs with congenital portosystemic vascular anomalies. *J Vet Intern Med* 1994;8:55-56.
81. Bunch SE, Jordan HL, Sellon RK, Cullen JM, Smith JE. Characterization of iron status in young dogs with portosystemic shunt. *Am J Vet Res* 1995;56(7):853-858.
82. Simpson KW, Meyer DJ, Boswood A, White RN, Maskell IE. Iron status and erythrocyte volume in dogs with congenital portosystemic vascular anomalies. *J Vet Intern Med* 1997;11:14-19.
83. Niles JD, Williams JM, Cripps PJ. Hemostatic profiles in 39 dogs with congenital portosystemic shunts. *Vet Surg* 2001;30:97-104.
84. Kummeling A, Teske E, Rothuizen J, van Sluijs FJ. Coagulation profiles in dogs with congenital portosystemic shunts before and after surgical attenuation. *J Vet Intern Med* 2006;20:1319-1326.
85. Szatmári V, Rothuizen J, Voorhout G. Standard planes for ultrasonographic examination of the portal system in dogs *J Am Vet Med Assoc* 2004;224(5):713-727.

86. Szatmári V. Ultrasonography of portosystemic shunting in dogs; Doppler studies before, during and after surgery. PhD Thesis, Utrecht University, 2004. <http://igitur-archive.library.uu.nl/dissertations/2004-0423-090416/inhoud.htm>
87. Szatmári V, van Sluijs FJ, Rothuizen J, Voorhout G. Ultrasonographic assessment of hemodynamic changes in the portal vein during surgical attenuation of congenital extrahepatic portosystemic shunts in dogs. *J Am Vet Med Assoc* 2004;224:395-402.
88. Koblik PD, Komtebedde J, Yen C-K, Hornof WJ. Use of transcolonic ^{99m}Tc-pertechnetate as a screening test for portosystemic shunts in dogs. *J Am Vet Med Assoc* 1990;196(6):925-930.
89. Meyer HP, Rothuizen J, van den Brom WE, Voorhout G, van Sluijs FJ. Quantification of portosystemic shunting in dogs by ultrasound-guided injection of ^{99m}Tc-macroaggregates into a splenic vein. *Res Vet Sci* 1994;57:58-62.
90. Suter PF. Portal vein anomalies in the dog: their angiographic diagnosis. *J Am Vet Rad Soc* 1975;16(3):84-97.
91. White RN, MacDonald NJ, Burton CA. Use of intraoperative mesenteric portovenography in congenital portosystemic shunt surgery. *Vet Radiol Ultrasound* 2003;44(5):514-521.
92. Zwingenberger AL, Schwarz T, Saunders HM. Helical computed tomographic angiography of canine portosystemic shunts. *Vet Radiol Ultrasound* 2005;46(1):27-32.
93. Bertolini G, Rolla EC, Zotti A, Caldin M. Three-dimensional multiscale helical computed tomography techniques for canine extra-hepatic portosystemic shunt assessment. *Vet Radiol Ultrasound* 2006;47(5):439-443.
94. Seguin B, Tobias KM, Gavin PR, Tucker RL. Use of magnetic resonance angiography for diagnosis of portosystemic shunts in dogs. *Vet Radiol Ultrasound* 1999;40(3):251-258.

95. Torisu S, Washizu M, Hasegawa D, Orima H. Brain magnetic resonance imaging characteristics in dogs and cats with congenital portosystemic shunts. *Vet Radiol Ultrasound* 2005;46(6):447-451.
96. Taboda J. Medical management of animals with portosystemic shunts. *Sem Vet Med Surg Small Anim* 1990;5:107-119.
97. Meyer HP, Legemate DA, van den Brom WE, Rothuizen J. Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil. *Metabol Brain Dis* 1998;13(3):241-251.
98. Laflamme DP, Allen SW, Huber TL. Apparent dietary protein requirement of dogs with portosystemic shunt. *Am J Vet Res* 1993;54(5):719-723.
99. Watson PJ, Herrtage ME. Medical management of congenital portosystemic shunts in 27 dogs – a retrospective study. *J Smal Anim Pract* 1998;39:62-68.
100. Hardie EM, Kornegay JN, Cullen JM. Status epilepticus after ligation of portosystemic shunts. *Vet Surg* 1990;19(6):412-417.
101. Meyer HP, Rothuizen J, van Sluijs FJ, Voorhout G, van den Brom WE. Progressive remission of portosystemic shunting in 23 dogs after partial closure of congenital portosystemic shunts. *Vet Rec* 1999;144:333-337.
102. Vogt JC, Krahwinkel DJ, Bright RM, Daniel GB, Toal RL, Rohrbach B. Gradual occlusion of extraheptic portosystemic shunts in dogs and cats using the ameroid constrictor. *Vet Surg* 1996;25:495-502.
103. Sereda CW, Adin CA. Methods of gradual vascular occlusion and their applications in treatment of congenital portosystemic shunts in dogs: a review. *Vet Surg* 2005;34:83-91.
104. White RN, Trower ND, McEvoy FJ, Garden OA, Boswood A. A method for controlling portal pressure after attenuation of intrahepatic portocaval shunts. *Vet Surg* 1996;25:407-413.

105. Wolschrijn CF, Mahapokai W, Rothuizen J et al. Gauged attenuation of congenital portosystemic shunts: results in 160 dogs and 15 cats. *Vet Q* 2000;22:94-98.
106. Frankel D, Seim H, MacPhail C, Monnet E. Evaluation of cellophane banding with and without intraoperative attenuation for treatment of congenital extrahepatic portosystemic shunts in dogs. *J Am Vet Med Assoc* 2006;228:1355-1360.
107. Youmans KR, Hunt GB. Cellophane banding for the gradual attenuation of single extrahepatic portosystemic shunts in eleven dogs. *Aust Vet J* 1998;76(8):531-537.
108. Hunt GB, Kummeling A, Tisdall PLC, Marchevsky AM, Liptak JM, Youmans KR, Goldsmid SE, Beck JA. Outcomes of cellophane banding for congenital portosystemic shunts in 106 dogs and 5 cats. *Vet Surg* 2004;33:25-31.
109. Besancon MF, Kyles AE, Griffey SM, Gregory CR. Evaluation of the characteristics of venous occlusion after placement of an ameroid constrictor in dogs. *Vet Surg* 2004;33:597-605.
110. Mehl ML, Kyles AE, Hardie EM, Kass PH, Adin CA, Flynn AK, De Cock HE, Gregory CR. Evaluation of ameroid ring constrictors for treatment for single extrahepatic portosystemic shunts in dogs: 168 cases (1995-2001). *J Am Vet Med Assoc* 2005;226:2020-2030.
111. Kyles AE, Gregory CR, Jackson J, Ilkiw JE, Pascoe PJ, Adin C, Samii VF, Herrgesell E. Evaluation of a portocaval venograft and ameroid ring for the occlusion of intrahepatic portocaval shunts in dogs. *Vet Surg* 2001;30:161-169.
112. Mehl ML, Kyles AE, Case JB, Kass PH, Zwingenberger A, Gregory CR. Surgical management of left divisional intrahepatic portosystemic shunts: outcome after partial ligation of, or ameroid ring constrictor placement on, the left hepatic vein in twenty-eight dogs (1995-2005). *Vet Surg* 2007;36:21-30.

113. Miller JM, Fowler JD. Laparoscopic portosystemic shunt attenuation in two dogs. *J Am Anim Hosp Assoc* 2006;42:160-164.
114. Léveillé R, Johnson SE, Birchard SJ. Transvenous coil embolization of portosystemic shunt in dogs. *Vet Radiol Ultrasound* 2003;44(1):32-36.
115. Weisse C, Schwarz K, Stronger R, Mondschein JI, Solomon JA. Transjugular coil embolisation of an intrahepatic shunt in a cat. *J Am Vet Med Assoc* 2002;221(9):1287-1291.
116. Scavelli TD. Complications associated with the diagnostic, medical, and surgical management of portosystemic shunts. *Probl Vet Med* 1989;1:145-158.
117. Roy RG, Post GS, Waters DJ, Hardy RM. Portal vein thrombosis as a complication of portosystemic shunt ligation in two dogs. *J Am Anim Hosp Assoc* 1992;28:53-58.
118. Tisdall PLC, Hunt GB, Youmans KR, Malik R. Neurologic dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts. *J Small Anim Pract* 2000;41:539-546.
119. Yool DA, Kirby BM. Neurologic dysfunction in three dogs and one cat following attenuation of intrahepatic portosystemic shunts. *J Small Anim Pract* 2002;43:171-176.
120. Heldmann E, Holt DE, Brockman DJ, Brown DC, Perkowski Z. Use of propofol to manage seizure activity after surgical treatment of portosystemic shunts. *J Small Anim Pract* 1999;40:590-594.
121. Johnson SE. Portal hypertension Part II. Clinical assessment and treatment. *Comp Cont Edu Pract Vet Small Anim* 1987;9(9):917-928.
122. Havig M, Tobias KM. Outcome of ameroid constrictor occlusion of single congenital extrahepatic portosystemic shunts in cats: 12 cases (1993-2000). *J Am Vet Med Assoc* 2002;220:337-341.

123. Kyles AE, Hardie EM, Mehl M, Gregory CR. Evaluation of ameroid ring constrictors for the management of single extrahepatic portosystemic shunts in cats: 23 cases (1996-2001). *J Am Vet Med Assoc* 2002;220:1341-1347.

Neoplastic Disorders

1. Patnaik AK, Hurvitz AI, Lieberman PH. Canine hepatic neoplasms: a clinicopathologic study. *Vet Pathol* 1980; **17**: 553–64.

2. Strombeck DR. Clinicopathologic features of primary and metastatic neoplastic disease of the liver in dogs. *J Am Vet Med Assoc* 1978; **173**: 267–9.

3. Engle GC, Brodey RS. A retrospective study of 395 feline neoplasms. *J Am Anim Hosp Assoc* 1969; **5**: 21–31.

4. Schmidt RE, Langham RF. A survey of feline neoplasms. *J Am Vet Med Assoc* 1967; **151**: 1325–8.

5. Balkman, C. Hepatobiliary neoplasia in dogs and cats. *Vet Clin Small Anim* 2009; **39**: 617-625.

6. Cullen JM, Popp JA. Tumors of the liver and gallbladder. In Meuten DJ, editor: *Tumors in domestic animals*, 4th ed., Ames, 2002, Iowa State Press.

7. Thamm DH. Hepatobiliary tumors. In Withrow SJ, MacEwen EG, editors: *Small animal clinical oncology*, ed. 3, Philadelphia, 2001, WB Saunders.

8. Hirao K, Matsumura K, Imagawa A, et al. Primary neoplasms in dog liver induced by diethylnitrosamine. *Cancer Res.* 1974; 34(8):1870-82.

9. Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. *Nature Reviews Cancer* 2008; **8**: 147–156.

10. Boomkens SY, Spee B, Ijzer J et al. The establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patterns. *Comp Hepatol* 2004; **3**: 9.

11. Ramos-Vara JA, Miller MA and Johnson GC. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7. *Vet Pathol* 2001; **38**: 636–643.

12. Patnaik AK, Newman SJ, Scase T, et al. Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study. *Vet Pathol* 2005; **42**: 140-146.

13. Hayes HM, Morin MM, Rubenstein DA. Canine biliary carcinoma: epidemiological comparisons with man. *J Comp Pathol* 1983; **93**: 99-102.

14. Kocak M, Kocak S, Kocak S, et al. Biliary carcinoma in men and dogs. *Coll Antropol.* 2009, 33(3):811-4.

15. Romero-Gallo J, Sozmen EG, Chytil A, et al. Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. *Oncogene.* 2005; 24(18):3028-3041.

16. Yoon YJ, Chang HY, Ahn SH, et al., MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *Carcinogenesis.* 2008, 29(6):1192-1196.

17. Borlak J, Meier T, Halter R, et al. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. *Oncogene.* 2005; 24(11):1809-19.

18. Cogliati B, Aloia TP, Bosch RV, et al. Identification of hepatic stem/progenitor cells in canine hepatocellular and cholangiocellular carcinoma. *Vet Comp Oncol.* 2010, 8(2):112-121.
19. Liptak J. Hepatobiliary tumors. In Withrow S and Vail D: *Withrow and MacEwen's Small Animal Clinical Oncology.* Elsevier, 2006: 483-491.
20. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. *Hepatology.* 2009;49(2):658-64. Erratum in: *Hepatology.* 2009; 49(3):1058.
21. Mandell DC, VMD and Drobatz K: Feline hemoperitoneum: 16 cases (1986-1993). *J Vet Emerg Crit Care* 1995;5 (2):93-97.
22. Tashbaeva RE, Hwang DN, Song GS, et al. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. *Vet Pathol.* 2007; 44(5):600-606.
23. Badylak SF, Dodds J, Van Vleet JF. Plasma coagulation factor abnormalities in dogs with naturally occurring hepatic disease. *Am J Vet Res* 1983; 44: 2336–2340.
24. Krotje LJ, Fix AS, Potthoff AD. Acquired myasthenia gravis and cholangiocellular carcinoma in a dog. *J Am Vet Med Assoc.* 1990; 197(4):488-490.
25. Evans SM. The radiographic appearance of primary liver neoplasia in dogs. *Vet Rad* 1987; **28**: 192–196.
26. Liptak JM, Dernell WS, Monnet E, et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992–2002). *J Am Vet Med Assoc* 2004; 225: 1225–1230.
27. Patnaik AK, Hurvitz AI, Lieberman PH, *et al.* Canine hepatocellular carcinoma. *Vet Pathol* 1981; 18: 427–438.

28. Post G, Patnaik AK. Nonhematopoietic hepatic neoplasms in cats: 21 cases (1983-1988). *J Am Vet Med Assoc*. 1992 Oct 1;201(7):1080-1082.
29. Lawrence HJ, Erb HN, Harvey HJ. Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972 to 1991). *Vet Surg* 1994; **23**:365-368.
30. Adler R and Wilson DW. Biliary cystadenomas of cats. *Vet Pathol* 1995; **32**: 415-418.
31. Nyland TG, Koblik PD, Tellyer SE. Ultrasonographic evaluation of biliary cystadenomas in cats. *Vet Radiol Ultrasound*, 1999; 40: 300-306.
32. Patnaik AK, Lieberman PH, Hurvitz AI, et al. Canine hepatic carcinoids. *Vet Pathol*. 1981 Jul;18(4):445-453.
33. Strombeck, D.R. and Guilford, W.G. Hepatic neoplasms. In Guilford, WG, Center, SA, Strombeck DR, Williams DA and Myer DJ (eds). *Stromberk's Small Animal Gastroenterology*, 3rd . 1996. pp847-859.)
34. Owen, L.N. (1980) *TNM Classification of Tumours in Domestic Animals*. World Health Organisation, Geneva.
35. Center SA, Slater MR, Manwarren T, et al. Diagnostic efficacy of serum alkaline phosphatase and gamma-glutamyltransferase in dogs with histologically confirmed hepatobiliary disease: 270 cases (1980–1990). *J Am Vet Med Assoc* 1992; **201**: 1258–1264.
36. Zini E, Glaus TM, Minuto F, et al. Paraneoplastic hypoglycemia due to an insulinlike growth factor type-II secreting hepatocellular carcinoma in a dog. *J Vet Intern Med* 2007; **21**: 193–195.
37. Lowseth LA, Gillett NA, Chang IY, et al. Detection of serum alpha-fetoprotein in dogs with hepatic tumors. *J Am Vet Med Assoc*. 1991; 199(6):735-741.

38. Kitao S, Yamada T, Ishikawa T, et al. Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma. *J Vet Diagn Invest.* 2006;18(3):291-295.
39. Yamada T, Fujita M, Kitao S, et al. Serum alpha-fetoprotein values in dogs with various hepatic diseases. *J Vet Med Sci.* 1999;61(6):657-659.
40. Feeney DA, Johnston GR, Hardy RM. Two-dimensional, gray-scale ultrasonography for assessment of hepatic and splenic neoplasia in the dog and cat, *J Am Vet Med Assoc* 1984; **184**: 68-70.
41. Newell SM, Selcer BA, Girard E, et al: Correlations between ultrasonographic findings and specific hepatic disease in cats: 72 cases (1985–1997), *J Am Vet Med Assoc* 1998; **213**: 94-97.
42. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. *J Am Vet Med Assoc* 2002; **220**: 1483–1490.
43. Clifford CA, Pretorius ES, Weisse C, et al: Magnetic resonance imaging of focal splenic and hepatic lesions in the dog. *J Vet Intern Med* 2004; 18:330-338.
44. Wang KY, Panciera DL, Al-Rukibat RK, et al. Accuracy of ultrasoundguided aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990–2000). *J Am Vet Med Assoc* 2004; 224: 75–78.
45. Stockhaus C, Van Den Ingh T, Rothuizen J, et al. A multistep approach in the cytologic evaluation of liver biopsy samples of dogs with hepatic diseases. *Vet Pathol.* 2004; 41(5):461-470.
46. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. *J Vet Intern Med.* 2008; 22(6):1373-9.

47. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar_®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. *Methods Enzymol* 2005; **407**: 597-612
48. Galle PR. Sorafenib in advanced hepatocellular carcinoma: we have won a battle not the war. *J Hepatol* 2008; **49**: 871-3.
49. London CA, Hannah AL, Zadovoskaya R, et al: Phase I dose escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. *Clin Cancer Res* 2003; **9**:2755-2768.
50. Lana S, U'ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. *J Vet Intern Med* 2007, **21**:764-976.
51. Gupta S, Yao Jc, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. *Cancer J* 2003; **9**: 261-7.
52. Weisse C, Clifford CA, Holt D, et al. Percutaneous arterial embolization and chemoembolization for treatment of benign and malignant tumors in three dogs and a goat. *J Am Vet Med Assoc* 2002; **221**: 1430-6.
53. Cave TA, Johnson V, Beths T et al. Treatment of unresectable hepatocellular adenoma in dogs with transarterial iodized oil and chemotherapy with and without an embolic agent: a report of two cases. *Vet Comp Oncol* 2003; **1**: 191-199.
54. Kosovsky JE, Manfra-Marretta S, Matthiesen DT, et al. Results of partial hepatectomy in 18 dogs with hepatocellular carcinoma. *J Am Anim Hosp Assoc* 1989; **25**: 203–206.
55. Trigo FJ, Thompson H, Breeze RG, et al. The pathology of liver tumours in the dog. *J Comp Pathol.* 1982; **92**(1):21-39.

56. Bjorling DE, Prasse KW, Holmes RA: Partial hepatectomy in dogs. *Compend Contin Educ Pract Vet* 1985; 7:257.
56. Bartlett DL, Carr BI, Marsh JW. Cancer of the liver. In DeVita VT, Hellman S, Rosenberg SA, editors. *Cancer: principles and practice of oncology*, Philadelphia, 2005, Lippincott Williams & Wilkins.
57. Ogilvie GK, et al: Efficacy of mitoxantrone against various neoplasms in dogs. *J Am Vet Med Assoc* 1991; 198:1618.
58. Shen FZ, Wang J, Liang J, et al. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? *Int J Exp Pathol*. 2010; 91(1):10-16.
59. Patnaik AK. A morphologic and immunocytochemical study of hepatic neoplasms in cats. *Vet Pathol*. 1992;29(5):405-415.
60. Pastor J, Majo N, Arbona C, et al. Sclerosing adenocarcinoma of the extra-hepatic bile duct in a cat. *Vet Rec* 1997; 140: 367-368
61. Cullen JM and Popp JA. Tumors of the liver and gall bladder. In: *Tumors in Domestic Animals*, 4th edn., DJMeuten, ed., Ames, Iowa State Press, 2002:483–508.
62. Trout NJ, Berg J, McMillan MC, et al. Surgical treatment of hepatobiliary cystadenomas in cats: five cases (1988–1993). *J Am Vet Med Assoc* 1995; 206: 505.
63. Adler R, Wilson DW. Biliary cystadenoma of cats. *Vet Pathol*. 1995; 32(4):415-8.
64. Morrell CN, Volk MV, Mankowski JL. A carcinoid tumor in the gallbladder of a dog. *Vet Pathol* 2002; 39: 756-758.
65. Patnaik AK, Lieberman PH, Erlandson RA, et al. Hepatobiliary neuroendocrine carcinoma in cats: a clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases. *Vet Pathol*. 2005; 42(3):331-337.

66. Willard MD, Dunstan RW, Faulkner J. Neuroendocrine carcinoma of the gallbladder in a dog. *J Am Vet Med Assoc.* 1988; 192(7):926-928.
67. Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs with histiocytic sarcoma. *J Vet Intern Med* 2007; 21: 121–126.
68. Dhaliwal RS, Johnson TO, Kitchell BE. Primary extraskeletal hepatic osteosarcoma in a cat. *J Am Vet Med Assoc.* 2003; 222(3):340-342,
69. Gabor LJ, Goldschmidt M, Lamb M, et al. Feline epitheliotropic intestinal malignant lymphoma: 10 cases (1997-2000). *J Vet Intern Med* 2003; 17: 326-331.
70. Louwerens M, London CA, Pedersen NC, et al. Feline lymphoma in the post-feline leukemia virus era. *J Vet Intern Med.* 2005; 19(3):329-35.
71. Liska WD, MacEwen EG, Zaki FA et al. Feline systemic mastocytosis: a review and results of splenectomy in seven cases. *J Am Anim Hosp Assoc* 1979; 15:589-597.
72. Marconato L, Bettini G, Giacoboni C, et al. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. *J Vet Intern Med.* 2008; 22(4):1001-1007.
73. Hammer AS, Sikkema DA: Hepatic neoplasia in the dog and cat. *Vet Clin North Am Small Anim Pract* 1995; 25:419-435.
74. Rassnick KM, Williams LE, Kristal O, *et al.* Lomustine for treatment of mast cell tumors in cats: 38 cases (199-2005). *J Am Vet Med Assoc* 2008; **232**: 1200-1205.
75. Bergman JR. Nodular hyperplasia in the liver of the dog: an association with changes in the Ito cell population. *Vet Pathol.* 1985; 22(5):427-438.
76. Fabry A, Benjamin SA, Angleton GM. Nodular hyperplasia of the liver in the beagle dog. *Vet Pathol.* 1982; 19(2):109-119.

77. Prause LC, Twedt DC: hepatic nodular hyperplasia. In Kirk's current veterinary therapy XIII. Bonagura JD (ed). Philadelphia: WB Saunders, 1999, p.675-676.
78. van den Ingh T, van Winkle T, Cullen JM, et al. Morphological classification of parenchymal disorders of the canine and feline liver. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease. Edinburgh: Saunders Elsevier, 2006.
79. Voros K, Vrabely L, Papp L et al: Correlation of ultrasonographic and pathomorphologic findings in canine hepatic diseases. J Small Anim Pract 32:627, 1991.

Metabolic Disorders

1. Scherk MA, Center SA. Toxic, Metabolic, Infectious, and Neoplastic Liver Diseases. In: Textbook of Veterinary Internal Medicine, Ettinger SJ, Feldman EC (eds). Elsevier, Philadelphia PA, 2010; pp1672-1689.
2. Brown B, Mauldin GE, Armstrong J, Moroff SD, Mauldin GN. Metabolic and hormonal alterations in cats with hepatic lipidosis. J Vet Intern Med. 2000 Jan-Feb;14(1):20-6.
3. Center SA, Crawford MA, Guida L, Erb HN, King J. A retrospective study of 77 cats with severe hepatic lipidosis: 1975-1990. J Vet Intern Med. 1993 Nov-Dec;7(6):349-59.
4. Center SA. Feline hepatic lipidosis. Vet Clin North Am Small Anim Pract. 2005 Jan;35(1):225-69. Review.
5. Akol KG, Washabau RJ, Saunders HM, Hendrick MJ. Acute pancreatitis in cats with hepatic lipidosis. J Vet Intern Med. 1993 Jul-Aug;7(4):205-9.
6. Morris JG, Rogers QR. Ammonia intoxication in the near adult cat as a result of a dietary deficiency of arginine. Science 1978; 199: 431-432.
7. MacDonald ML, Rogers QR, Morris JG. Nutrition of the domestic cat, a domestic carnivore. Ann Rev Nutr 4: 521-562, 1984.

8. Rogers QA, Morris JG. Lack of hepatic enzyme adaptation to low and high levels of dietary protein in the adult cat. Enzyme 1977; 22: 348-356
9. VanSteenhouse JL, Dimski DS, Swenson DH, et al. Urinary orotic acid-to-creatinine ratios in cats with hepatic lipidosis. *Am J Vet Res* 1999; 60: 753-754.
10. Demacker PN, van Heijst PJ, Hak-Lemmers HL et al. A study of the lipid transport system in the cat. *Atherosclerosis* 1987; 66: 113-123
11. Hall JA, Barstad LA, Connor WE. Lipid composition of hepatic and adipose tissues from normal cats and from cats with idiopathic lipidosis. *J Vet Intern Med* 1997; 11: 238-242.
12. Justine RB, Hohenhaus AE. Hypophosphatemia associated with enteral alimentation in cats. *J Vet Intern Med.* 1995 Jul-Aug;9(4):228-233
13. Feeney DA, Anderson KL, Ziegler LE, Jessen CR, Daubs BM, Hardy RM. Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. *Am J Vet Res.* 2008 Feb;69(2):212-21.
14. Newell SM, Selcer BA, Girard E, Roberts GD, Thompson JP, Harrison JM. Correlations between ultrasonographic findings and specific hepatic diseases in cats: 72 cases (1985-1997). *J Am Vet Med Assoc.* 1998 Jul 1;213(1):94-8.
15. Willard MD, Weeks BR, Johnson M. Fine-needle aspirate cytology suggesting hepatic lipidosis in four cats with infiltrative hepatic disease. *J Feline Med Surg.* 1999 Dec;1(4):215-20.
16. Center SA, Guida L, Zanelli MJ, Dougherty E, Cummings J, King J. Ultrastructural hepatocellular features associated with severe hepatic lipidosis in cats. *Am J Vet Res.* 1993 May;54(5):724-31.
17. Center SA, Warner K, Corbett J, Randolph JF, Erb HN. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. *J Vet Intern Med* 2000 May-Jun;14(3):292-7.

18. Biourge VC. Nutrition and liver disease. *Semin Vet Med Surg (Small Anim)*.1997 Feb;12(1):34-44. Review.
19. Blanchard G et al: Dietary L-carnitine supplementation in obese cats alters carnitine metabolism and decreases ketosis during fasting and induced hepatic lipidosis. *J Nutr* 132:204-210, 2002.
20. Cantafora A, Blotta I, Rossi SS, Hofmann AF, Sturman JA. Dietary taurine content changes liver lipids in cats. *J Nutr*. 1991 Oct;121(10):1522-8.
21. Hickman, M. A., S. R. Cox, et al.. "Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats." *J Vet Pharm Therap* 31(3): 220-229, 2008.
22. Peterson ME: Hyperthyroidism. In Ettinger SJ, Feldman EC (eds): *Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat*, 5th ed. Philadelphia, WB Saunders Co, 2000, pp 1400-1419.
23. Peterson ME et al: Feline hyperthyroidism: pretreatment clinical and laboratory evaluation of 131 cases. *J Am Vet Med Assoc* 183:103, 1983.
24. Sola J, Pardo-Mindán FJ, Zozaya J, Quiroga J, Sangro B, Prieto J. Liver changes in patients with hyperthyroidism. *Liver* 1991; 11: 193-197.
25. Doran GR. Serum enzyme disturbances in thyrotoxicosis and myxoedema. *J R Soc Med* 1978; 71: 189-194.
26. Gürlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. *J Clin Gastroenterol* 1997; 24: 180-183.
27. Peterson ME et al: Serum thyroid hormone concentrations fluctuate in cats with hyperthyroidism. *J Vet Intern Med* 1:142, 1987.

28. Peterson ME, Gamble DA: Effect of nonthyroidal illness on serum thyroxine concentrations in cats: 494 cases (1988). *J Am Vet Med Assoc* 197;1203, 1990.
29. Mooney CT et al: Effect of illness not associated with the thyroid gland on serum total and free thyroxine concentrations in cats. *J Am Vet Med Assoc* 208:2004, 1996.
30. McLoughlin MA et al: Influence of systemic nonthyroidal illness on serum concentration of thyroxine in hyperthyroid cats. *J Am Anim Hosp Assoc* 29:227, 1993.
31. Mooney CT: Feline hyperthyroidism. Diagnostics and therapeutics. *Vet Clin North Am Small Anim Pract* 31:963, 2001.
32. Malik R, Hodgson H. The relationship between the thyroid gland and the liver. *QJM* 2002; 95: 559-569 46.
33. Daher R, Yazbeck T, Jaoude JB, Abboud B. Consequences of dysthyroidism on the digestive tract and viscera. *World J Gastroenterol* 2009 June 21; 15(23): 2834-2838.
34. Byrne KP. Metabolic epidermal necrosis-hepatocutaneous syndrome. *Vet Clin North Am Small Anim Pract* 1999;29(6):1337-1355.
35. Kasper CS and McMurry K. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: Is hepatic impairment a clue to pathogenesis? *J Am Acad Dermatol* 1991;25(3):534-541.
36. Kimmel SE, Christiansen W, Byrne KP. Clinicopathological, ultrasonographic, and histopathological findings of superficial necrolytic dermatitis with hepatopathy in a cat. *J Am Anim Hosp Assoc*. 2003 Jan-Feb;39(1):23-7.
37. Allenspach, K., et al. Glucagon-producing neuroendocrine tumour associated with hypoaminoacidemia and skin lesions. *J Small Anim Pract* 2000;41:402–406.

38. Jacobson LS, Kirberger RM, Nesbit JW. Hepatic ultrasonography and pathological findings in dogs with hepatocutaneous syndrome: new concepts. *J Vet Intern Med.* 1995 Nov-Dec;9(6):399-404.
39. Badylak SF, Van Vleet JF: Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy. *Am J Vet Res* 42:1310-1318, 1980.
40. Solter PF et al: Hepatic total 3 α -hydroxy bile acids concentration and enzyme activities in prednisone-treated dogs. *Am J Vet Res* 55:1086-1092, 1994.
41. M Schaer and PE Ginn. Iatrogenic Cushing's syndrome and steroid hepatopathy in a cat. *J Amer Anim Hosp Asso*, Vol 35, Issue 1, 48-51.
42. Feldman EC: Comparison of ACTH response and dexamethasone suppression as screening tests in canine hyperadrenocorticism. *J Amer Vet Med Assoc* 182:505-510, 1983.
43. Mark RE, Feldman EC: Comparison of two low-dose dexamethasone suppression protocols as screening and discrimination tests in dogs with hyperadrenocorticism. *J Amer Vet Med Assoc* 197:1603-1606, 1990.
44. Kaplan AJ, Peterson ME, Kemppainen RJ: Effects of nonadrenal disease on the results of diagnostic tests for hyperadrenocorticism in dogs. *J Vet Intern Med* 8(2):161 (Abstract), 1994.
45. Peterson ME, Gilbertson SR, Drucker WD. Plasma cortisol response to exogenous ACTH in 22 dogs with hyperadrenocorticism caused by adrenocortical neoplasia. *J Amer Vet Med Assoc* 180:542-544, 1982.
46. Chastain CB, Franklin RT, Granham VK, et al: Evaluation of the hypothalamic pituitary-adrenal axis in clinically stressed dogs. *J Amer Anim Hosp Assoc* 22:435-441, 1986.
47. Contreras LN, Hane S, Tyrrell JB: Urinary cortisol in the assessment of pituitary-adrenal function: Utility of 24-hour and spot determinations. *J Clin Endocrinol Metab* 65:965-969, 1986.

48. Feldman EC, Mark RE: Urine cortisol:creatinine ratio as a screening test for hyperadrenocorticism in the dog. *J Amer Vet Med Assoc* 200;1637-1641, 1992.
49. Smiley LE, Peterson ME: Evaluation of a urine cortisol:creatinine ratio as a screening test for hyperadrenocorticism in dogs. *J Vet Intern Med* 7:163-168, 1993.
50. Beatty JA, Barrs VR, Martin PA, et al. Spontaneous hepatic rupture in six cats with systemic amyloidosis. *JSAP* 2002; 43: 355-363/
51. Loeven KO. Hepatic amyloidosis in two Chinese shar pei dogs. *JAVMA* 1994; 204: 1212-1216.
52. Rivas AL, Tintle L, Meyers-Wallen V, et al. Inheritance of renal amyloidosis in Chinese Shar-pei dogs. *J. Heredity* 1993; 84: 438-442.
53. Rivas AL, Tintle L, Kimball ES, et al. A canine febrile disorder associated with elevated interleukin-6. *Clin Immunol Immunopathol* 1992; 64: 36-45.
54. DiBartola Sp, Tarr MJ, Webb DM, et al. Familian renal amyloidosis in Chinese Shar-pei dogs. *JAVMA* 1990; 197: 483-487.
55. Clark L, Seawright AA. Amyloidosis associated with chronic hypervitaminosis A in cats. *Aus Vet J* 1968; 44: 584.
56. Ginzinger DG, Clee SM, Dallongeville J, et al. Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. *Eur J Clin Invest* 1999; 29: 17-26
57. Johnstone AC, Jones BR, Thompson JC, et al. The pathology of an inherited hyperlipoproteinemia of cats. *J Comp Path* 1990; 102: 125-137.
58. Datz CA, Backus RC, Fritsche KL. Dietary diacylglycerol oil has no effect on hypertriglyceridemia in lipoprotein lipase-deficient cats. *Brit J Nutr* 2009; 102: 1024-1029.

59. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. *Endocrinol Metab Clin North Am* 2007; 36: 595-615.
60. Liverini G, Iossa S, Barletta A. Relationship between resting metabolism and hepatic metabolism: effect of hypothyroidism and 24 hours fasting. *Horm Res* 1992; 38: 154-159
61. Panciera DL: Hypothyroidism in dogs: 66 cases (1987-1992), *J Am Vet Med Assoc* 204:761, 1994.
62. Dixon RM et al: Epidemiological, clinical, haematological and biochemical characteristics of canine hypothyroidism, *Vet Rec* 145:481, 1999.
63. Peterson ME et al: Measurement of serum total thyroxine, triiodothyronine, free thyroxine, and thyrotropin concentrations for diagnosis of hypothyroidism in dogs, *J Am Vet Med Assoc* 211:1396, 1997.
64. Dixon RM, Mooney CT: Evaluation of serum free thyroxine and thyrotropin concentrations in the diagnosis of canine hypothyroidism, *J Small Anim Pract* 40:72, 1999.
65. Kantrowitz LB et al: Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in dogs with nonthyroidal illness, *J Am Vet Med Assoc* 219:765, 2001.
66. Dixon RM et al: Treatment and therapeutic monitoring of canine hypothyroidism, *J Small Anim Pract* 43:334, 2002
67. Ferguson DC, Hoenig M: Reexamination of dosage regimens for L-thyroxine (T₄) in the dog: Bioavailability and persistence of TSH suppression, *J Vet Intern Med* 11:121, 1997.

Intra-Hepatic Biliary Disorders

1. van den Ingh TSGAM, Cullen JM, Twedt DC, et al. Morphological classification of biliary disorders of the canine and feline liver. In: Rothuizen J, Bunch SE, Charles JA, et al., eds.

WSAVA standards for clinical and histological diagnosis of canine and feline liver disease.

Edinburgh: Saunders Elsevier, 2006;61-76.

2. Gagne JM, Weiss DJ, Armstrong PJ. Histopathologic evaluation of feline inflammatory liver disease. *Vet Pathol.* 1996;33:521-526.

3. Center SA, Rowland PH. The cholangitis/cholangiohepatitis complex in the cat, *Proceedings of the ACVIM Forum.* 1994;766-771.

4. Rondeau MP. WSAVA classification and role of bacteria in feline inflammatory hepatobiliary disease. *Proceedings of the ACVIM Forum.* 2009;590-591.

5. Twedt DC, Janeczko SD, McCord KW, et al. Culture-independent detection of bacteria in feline inflammatory liver disease. *J Vet Intern Med.* 2009;23:729A.

6. Day DG. Feline cholangiohepatitis complex. *Vet Clin North Am Small Anim Pract.* 1995;25:375-385.

7. Weiss DJ, Gagne JM, Armstrong PJ. Relationship between inflammatory hepatic disease, inflammatory bowel disease, pancreatitis and nephritis in cats. *J Am Vet Med Assoc.* 1996;209:1114-1116.

8. Mayhew PD, Holt DE, McLear RC, et al. Pathogenesis and outcome of extrahepatic biliary obstruction in cats. *J Small Anim Pract.* 2002;43:247-253.

9. Morgan M, Rondeau M, Rankin S, et al. A survey of feline inflammatory hepatobiliary disease using the WSAVA classification. *J Vet Intern Med.* 2008;22:806A.

10. Gagne JM, Armstrong PJ, Weiss DJ, et al. Clinical features of inflammatory liver disease in cats: 41 cases (1983-1993). *J Am Vet Med Assoc.* 1999;214:513-516.

11. Newell SM, Selcer BA, Girard E, et al. Correlations between ultrasonographic findings and specific hepatic diseases in cats: 72 cases (1985-1997). *J Am Vet Med Assoc.* 1998;213:94-98.

12. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. *J Am Vet Med Assoc.* 2002;220:1483-1490.
13. Roth L. Comparison of liver cytology and biopsy diagnoses in dogs and cats: 56 cases. *Vet Clin Pathol.* 2001;30:35-38.
14. Wang KY, Panciera DL, Al-Rukibat RK, et al. Accuracy of ultrasound-guided fine needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). *J Am Vet Med Assoc.* 2004;224:75-78.
15. Savary-Bataille KCM, Bunch SE, Spaulding KA, et al. Percutaneous ultrasound-guided cholecystocentesis in healthy cats. *J Vet Intern Med.* 2003;17:298-303.
16. Wagner KA, Hartmann FA, Trepanier LA. Bacterial culture results from liver, gallbladder, or bile in 248 dogs and cats evaluated for hepatobiliary disease: 1998–2003. *J Vet Intern Med.* 2007;21:417–424.
17. Morgan M, Rankin S, Berent A, et al. Prospective evaluation for bacterial infection in hepatic tissue and bile of cats with diffuse hepatobiliary disease. *J Vet Intern Med.* 2008;22:806A.
18. Buote NJ, Mitchell SL, Penninck D, et al. Cholecystoenterostomy for treatment of extrahepatic biliary tract obstruction in cats: 22 cases (1994–2003). *J Am Vet Med Assoc.* 2006;228:1376-1382.
19. Mayhew PD, Weisse CW. Treatment of pancreatitis-associated extrahepatic biliary tract obstruction by choledochal stenting in 7 cats. *J Small Anim Pract.* 2008;49:133-138.
20. Warren AL. Advances in characterization of feline nonsuppurative cholangitis/cholangiohepatitis syndrome. *Proceedings of the ACVIM Forum.* 2009;585-587.
21. Weiss DJ, Gagne JM, Armstrong PJ. Characterization of portal lymphocytic infiltrates in feline liver. *Vet Clin Pathol.* 1995;24:91-95.

22. Lucke VM, Davies JD. Progressive lymphocytic cholangitis in the cat. *J Sm Anim Pract.* 1984;25:249-260.
23. Day MJ. Immunohistochemical characterization of the lesions of feline progressive lymphocytic cholangitis/cholangiohepatitis. *J Comp Path.* 1998;119:135-1347.
24. Boomkens SY, Kusters JG, Hoffman G, et al. Detection of *Helicobacter pylori* in bile of cats. *FEMS Immunol Med Microbiol.* 2004;42:307-311.
25. Greiter-Wilke A, Scanziani E, Soldati S, et al. Association of *Helicobacter* with cholangiohepatitis in cats. *J Vet Intern Med.* 2006;20:822–827.
26. Bowman DD, Hendrix CM, Lindsay DS, et al. *Feline clinical parasitology.* 1st ed. Ames: Iowa State University Press, 2002.
27. Bielsa LM, Greiner EC. Liver flukes (*Platynosomum concinnum*) in cats. *J Am Anim Hosp Assoc.* 1985;21:269-274.
28. Lewis DT, Malone JB, Taboada J. Cholangiohepatitis and choledochectasia associated with *Amphimerus psuedofelineus* in a cat. *J Am Anim Hosp Assoc.* 1991;27:156-162.
29. Foley RH. *Platynosomum concinnum* infection in cats. *Compendium on continuing education for the practicing veterinarian.* 1994;16:1271-1274.
30. Haney DR, Christiansen JS, Toll J. Severe cholestatic liver disease secondary to liver fluke (*Platynosomum concinnum*) infection in three cats. *J Am Anim Hosp Assoc.* 2006;42:234-237.
31. van den Ingh TS, Rothuizen J, van Zinnicq Bergman HM. Destructive cholangiolitis in seven dogs. *Vet Q.* 1988; 10:240–245.
32. Gabriel A, van den Ingh TSGAM, Clercx C, et al. Suspected drug-induced destructive cholangitis in a young dog. *J Small Anim Pract.* 2006;47:344-348.

33. LaCroix JA, Pulley LT. Primary cholangiohepatitis in a dog. *J Am Anim Hosp Assoc.* 1974;10:55-57.
34. Forrester SD, Rogers KS, Relford RL. Cholangiohepatitis in a dog. *J Am Vet Med Assoc.* 1992;200:1704-1706.
35. Neel JA, Tarigo J, Grindem CB. Gallbladder aspirate from a dog. *Vet Clin Pathol.* 2006;35:467-470.
36. O'Neill EJ, Day MJ, Hall EJ, et al. Bacterial cholangitis/cholangiohepatitis with or without concurrent cholecystitis in four dogs. *J Small Anim Pract.* 2006;47:325-335.
37. Ghaffari MS, Dezfoulian O, Marjani M, et al. Concurrent bacterial cholecystitis and cholangitis in a diabetic Spitz dog. *Comp Clin Pathol.* 2009;18:337-340.
38. Mendham JH, Rozel JF, Bovee KC. Clinical-pathologic conference. *J Am Vet Med Assoc.* 1969;154:935-944.
39. Van den Ingh TS, Rothuizen J. Congenital cystic disease of the liver in seven dogs. *J Comp Pathol.* 1985;95:405-414.
40. Gorlinger S, Rothuizen J, Bunch S, et al. Congenital dilatation of the bile ducts (Caroli's disease) in young dogs. *J Vet Intern Med.* 2003;17:28-32.
41. Last RD, Hill JM, Roach M, et al. Congenital dilatation of the large and segmental intrahepatic bile ducts (Caroli's disease) in two Golden retriever littermates. *J S Afr Vet Assoc.* 2006;77:210-214.
42. McKenna SC, Carpenter JL. Polycystic disease of the kidney and liver in the Cairn terrier. *Vet Pathol.* 1980;17:436-442.
43. McAloose D, Casal M, Patterson DF, et al. Polycystic kidney and liver disease in two related West Highland White Terrier litters. *Vet Pathol.* 1998;35:77-81.

44. Bosje JT, van den Ingh TSGAM, van der Linde-Sipman JS. Polycystic kidney and liver disease in cats. *Vet Q*. 1998;20:136-139.
45. Eaton KA, Biller DS, DiBartola SP, et al. Autosomal dominant polycystic kidney disease in persian and persian-cross cats. *Vet Pathol*. 1997;34:117-126.
46. Hampson ECGM, Filippich LJ, Kelly WR, et al. Congenital biliary atresia in a cat: a case report. *J Small Anim Pract*. 1987;28:39-48.
47. Schulze C, Rothuizen J, Van Sluijs FJ, et al. Extrahepatic biliary atresia in a border collie. *J Small Anim Pract*. 2000;41:27-30.
48. van den Ingh TS, Rothuizen J, van den Brom WE. Extrahepatic cholestasis in the dog and the differentiation of extrahepatic and intrahepatic cholestasis. *Vet Q*. 1986;8:150-157.
49. Taboada J, Meyer DJ. Cholestasis associated with extrahepatic bacterial infection in five dogs. *J Vet Intern Med*. 1989;3:216-221.
50. Charles JA, Cullen JM, van den Ingh TSGAM, et al. Morphological classification of neoplastic disorders of the canine and feline liver. In: Rothuizen J, Bunch SE, Charles JA, et al., eds. *WSAVA standards for clinical and histological diagnosis of canine and feline liver disease*. Edinburgh: Saunders Elsevier, 2006;117-124.
51. Patnaik AK, Hurvitz AI, Lieberman PH. Canine hepatic neoplasms: a clinicopathologic study. *Vet Pathol*. 1980;17:553-564.
52. Trigo FJ, Thompson H, Breeze RG, et al. The pathology of liver tumors in the dog. *J Comp Pathol*. 1982;92:21-39.
53. Hayes HM, Morin MM, Rubenstein DA. Canine biliary carcinoma: epidemiological comparisons with man. *J Comp Pathol*. 1983;93:99-107.

54. Patnaik AK. A morphologic and immunohistochemical study of hepatic neoplasms in cats. *Vet Pathol.* 1992;29:405-415.
55. Post G, Patnaik AK. Nonhematopoietic hepatic neoplasms in cats: 21 cases (1983-1988). *J Am Vet Med Assoc.* 1992;201:1080-1082.
56. Lawrence HJ, Erb HN, Harvey HJ. Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972-1991). *Vet Surg.* 1994;23:365-368.
57. Adler R, Wilson DW. Biliary cystadenomas of cats. *Vet Pathol.* 1995;32:415-418.
58. Nyland TG, Koblik TD, Tellyer SE. Ultrasonographic evaluation of biliary cystadenomas in cats. *Vet Radiol Ultrasound.* 1999;40:300-306.
59. Fry PD, Rest JR. Partial hepatectomy in two dogs. *J Small Anim Pract.* 1993;34:192-195.

Extra Hepatic Biliary Disorders

1. Fahie MA, Martin RA. Extrahepatic biliary tract obstruction: a retrospective study of 45 cases (1983-1993). *J Amer Anim Hosp Assoc* 31: 478, 1995.
2. Besso JG, Wrigley RH, Gliatto JM, et al. Ultrasonographic appearance and clinical findings in 14 dogs with gallbladder mucocele. *Vet Radiol Ultra* 41: 261, 2000.
3. Pike FS, Berg J, King NW, et al. Gallbladder mucocele in dogs: 30 cases (2000-2002). *J Amer Vet Med Assoc* 224: 1615, 2004.
4. Kirpensteijn J, Fingland RB, Ulrich T, et al. Cholelithiasis in dogs: 29 cases (1980-1990). *J Amer Vet Med Assoc* 202(7): 1137, 1993.
5. Haney D, Christiansen J, Toll J. Severe cholestatic liver disease secondary to liver fluke (*Platynosomum concinnum*) infection in three cats. *J Amer Anim Hosp Assoc* 42: 234, 2006.
6. Mayhew PD, Holt DE, McLear RC, et al. Pathogenesis and outcome of extrahepatic biliary obstruction in cats. *J Small Anim Pract* 43: 247, 2002.

7. Buote N, Mitchell S, Penninck D, et al. Cholecystoenterostomy for treatment of extrahepatic biliary tract obstruction in cats: 22 cases (1994-2003). *J Amer Vet Med Assoc* 228: 1376, 2006.
8. {AU: Provide citation}
9. O'Neill E, Day M, Hall E, et al. Bacterial cholangitis/cholangiohepatitis with or without concurrent cholecystitis in four dogs. *J Small Anim Pract* 47: 325, 2006.
9. Greiter-Wilke A, Scanziani E, Soldati S, et al. Association of *Helicobacter* with cholangiohepatitis in cats. *J Vet Intern Med* 20: 822, 2006.
10. Amsellem P, Seim H, MacPhail C, et al. Long-term survival and risk factors associated with biliary surgery in dogs: 34 cases (1994-2004). *J Amer Vet Med Assoc* 229: 1451, 2006.
11. Church EM, Mattheisen DT. Surgical treatment of 23 dogs with necrotizing cholecystitis. *J Amer Anim Hosp Assoc* 24: 305, 1988.
12. Holt D, Mehler S, Mayhew P, et al. Canine gallbladder infarction: 12 cases (1993-2003). *Vet Path* 41: 416, 2004.
13. Eich CS, Ludwig LL. Surgical treatment of cholelithiasis in cats: a study of nine cases. *J Amer Anim Hosp Assoc* 38: 290, 2002.
14. Aguirre A, Center S, Randolph J, et al. Gallbladder disease in Shetland Sheepdogs: 38 cases (1995-2005). *J Amer Vet Med Assoc* 231: 79, 2007.
15. Bromel C, Smeak DD, Leveille R. Porcelain gallbladder associated with primary biliary adenocarcinoma in a dog. *J Amer Vet Med Assoc* 213: 1137, 1998.
16. Head L, Daniel G. Correlation between hepatobiliary scintigraphy and surgery or postmortem examination findings in dogs and cats with extrahepatic biliary obstruction, partial obstruction, or patency of the biliary system: 18 cases (1995-2004). *J Amer Vet Med Assoc* 227: 1618, 2005.

17. Bromel C, Barthez PY, Leveille R, et al. Prevalence of gallbladder sludge in dogs as assessed by ultrasonography. *Vet Radiol Ultra* 39: 206, 1998.
18. Savary-Bataille KCM, Bunch S, Spaulding KA, et al. Percutaneous ultrasound-guided cholecystocentesis in healthy cats. *J Vet Intern Med* 17: 298, 2003.
19. Gorlinger S, Rothuizen J, Bunch S, et al. Congenital dilatation of the bile ducts (Caroli's disease) in young dogs *J Vet Intern Med* 17: 28, 2003.
20. Hittmair KM, Vielgrader HD, Loupal G. Ultrasonographic evaluation of gallbladder wall thickness in cats. *Vet Radiol Ultra* 42: 149, 2001.
21. Herman B, Brawer R, Murtaugh R, et al. Therapeutic percutaneous ultrasound-guided cholecystocentesis in three dogs with extrahepatic biliary obstruction and pancreatitis. *J Amer Vet Med Assoc* 227: 1782, 2005.
22. Mayhew P, Richardson R, Mehler S, et al. Choledochal tube stenting for decompression of the extrahepatic portion of the biliary tract in dogs: 13 cases (2002-2005).: *J Amer Vet Med Assoc* 228: 1209, 2006.
23. Bacon NJ, White RAS. Extrahepatic biliary tract surgery in the cat: a case series and review. *J Small Anim Pract* 44: 231, 2003.
24. Worley DR, Hottinger HA, Lawrence HJ. Surgical management of gallbladder mucoceles in dogs: 22 cases (1999-2003). *J Amer Vet Med Assoc* 225: 1418, 2004.

Complications of Liver Disease

1. Bosch J, Enriquez R, Groszmann RJ, Storer EH. Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertensive model. *Hepatology* 1983 November;3(6):1002-7.

2. Rothuizen J. Important clinical syndromes associated with liver disease. *Vet Clin North Am Small Anim Pract* 2009 May;39(3):419-37.
3. Bertolini G, De LD, Ledda G, Caldin M. Esophageal varices due to a probable arteriovenous communication in a dog. *J Vet Intern Med* 2007 November;21(6):1392-5.
4. van d, I, Rothuizen J, Meyer HP. Portal hypertension associated with primary hypoplasia of the hepatic portal vein in dogs. *Vet Rec* 1995 October 21;137(17):424-7.
5. Bunch SE, Johnson SE, Cullen JM. Idiopathic noncirrhotic portal hypertension in dogs: 33 cases (1982-1998). *J Am Vet Med Assoc* 2001 February 1;218(3):392-9.
6. Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. *QJM* 2008 February;101(2):71-85.
7. Raffan E, McCallum A, Scase TJ, Watson PJ. Ascites is a negative prognostic indicator in chronic hepatitis in dogs. *J Vet Intern Med* 2009 January;23(1):63-6.
8. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. *Gut* 2008 August;57(8):1156-65.
9. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. *Lancet* 2005 January 29;365(9457):431-3.
10. Romero-Gomez M, Jover M, Galan JJ, Ruiz A. Gut ammonia production and its modulation. *Metab Brain Dis* 2009 March;24(1):147-57.
11. Holt DE, Washabau RJ, Djali S et al. Cerebrospinal fluid glutamine, tryptophan, and tryptophan metabolite concentrations in dogs with portosystemic shunts. *Am J Vet Res* 2002 August;63(8):1167-71.

12. Meyer HP, Chamuleau RA, Legemate DA, Mol JA, Rothuizen J. Effects of a branched-chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs. *Metab Brain Dis* 1999 June;14(2):103-15.
13. Proot S, Biourge V, Teske E, Rothuizen J. Soy protein isolate versus meat-based low-protein diet for dogs with congenital portosystemic shunts. *J Vet Intern Med* 2009 July;23(4):794-800.
14. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. *Hepatology* 2010 March;51(3):1062-9.
15. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. *World J Gastroenterol* 2010 July 21;16(27):3347-57.
16. Haussinger D. Regulation of hepatic ammonia metabolism: the intercellular glutamine cycle. *Adv Enzyme Regul* 1986;25:159-80.
17. Haussinger D. Structural-functional organization of hepatic glutamine and ammonium metabolism. *Biochem Soc Trans* 1987 June;15(3):369-72.
18. Prins M, Schellens CJ, van Leeuwen MW, Rothuizen J, Teske E. Coagulation disorders in dogs with hepatic disease. *Vet J* 2010 August;185(2):163-8.
19. Lisciandro SC, Hohenhaus A, Brooks M. Coagulation abnormalities in 22 cats with naturally occurring liver disease. *J Vet Intern Med* 1998 March;12(2):71-5.
20. Dunayer EK, Gwaltney-Brant SM. Acute hepatic failure and coagulopathy associated with xylitol ingestion in eight dogs. *J Am Vet Med Assoc* 2006 October 1;229(7):1113-7.
21. Center SA, Warner K, Corbett J, Randolph JF, Erb HN. Proteins invoked by vitamin K absence and clotting times in clinically ill cats. *J Vet Intern Med* 2000 May;14(3):292-7.

22. Bigge LA, Brown DJ, Penninck DG. Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996). *J Am Anim Hosp Assoc* 2001 May;37(3):228-33.
23. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. *Hepatology* 2006 February;43(2 Suppl 1):S45-S53.
24. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. *J Gastroenterol Hepatol* 2011 January;26 Suppl 1:203-12.
25. Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. *Pharmacol Res* 2008 August;58(2):129-36.
26. Schotanus BA, van d, I, Penning LC, Rothuizen J, Roskams TA, Spee B. Cross-species immunohistochemical investigation of the activation of the liver progenitor cell niche in different types of liver disease. *Liver Int* 2009 September;29(8):1241-52.
27. Benyon RC, Iredale JP. Is liver fibrosis reversible? *Gut* 2000 April;46(4):443-6.
28. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. *Hepatology* 2010 April;51(4):1445-9.
29. Friedman SL. Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol* 2010 August;7(8):425-36.
30. Watson PJ. Chronic hepatitis in dogs: a review of current understanding of the aetiology, progression, and treatment. *Vet J* 2004 May;167(3):228-41.
31. Ramachandran P, Iredale JP. Reversibility of liver fibrosis. *Ann Hepatol* 2009 October;8(4):283-91.

32. Kanemoto H, Ohno K, Sakai M et al. Blood hyaluronic acid as a marker for canine cirrhosis. *J Vet Med Sci* 2009 September;71(9):1251-4.
33. Spee B, Arends B, van d, I et al. Transforming growth factor beta-1 signalling in canine hepatic diseases: new models for human fibrotic liver pathologies. *Liver Int* 2006 August;26(6):716-25.
34. Fallowfield JA. Therapeutic Targets in Liver Fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2011 January 13.